Title of Invention

SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME

Abstract The present invention relates to novel oxindole derivatives of the general formula (I), wherein the substitutes A, B, R1, R2 and R3 are as defined in Claim 1, and medicaments containing the same for the prophylaxis and / or treatment of vasopressin-dependent or oxytocin-dependent diseases.
Full Text FORM 2
The Patents Act, 1970
(39 of 1970)
&
The Patent Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rule 13)
"SUBSTITUTED OXESfDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME"
Abbott GmbHAr Co., KG, a company incorporated in Germany, having its Registered Office at Max-Planck-Ring 2,65205 Wiesbaden, Germany
The following specification particularly describes the invention and the manner in which it is to be performed

1
Substituted oxindole derivatives and medicaments containing the
same
The present invention relates to novel oxindole derivatives and medicaments containing the same for the treatment of diseases.
Vasopressin is an endogenous hormone that has a very wide range of effects on organs and tissue. It is suspected that the vasopressin system plays a role in various health conditions, such as cardiac insufficiency and high blood pressure. Currently, three receptors (Via, V1b or V3 and V2) are known, by means of which vasopressin imparts its numerous effects. For this reason, antagonists of these receptors are being examined as possible new therapeutic approaches for the treatment of diseases (M. Thibonnier, Exp. Opin. Invest. Drugs 1998, 7(5), 729-740).
In the application under consideration, novel substituted oxindoles are described that carry an arylsulfonyl group in the 1-position. 1-phenyl-sulfonyl-1,3-dihydro-2H-indole-2-ones have already been described as ligands of the vasopressin receptors. In WO 93/15051, WO95/18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/164668 and WO 1/98295, derivatives have been described that are derived from the oxindole skeleton and that carry arylsulfonyl groups in the 1-position. These compounds essentially differ in the substitution in the 3-position.
In particular, in WO 93/15051 and WO 98/25901, 1-phenyl-sulfonyl-1,3-dihydro-2H-indole-2-ones are described as ligands of the vasopressin receptors in which tv/c a!!'.y! radicals, which likewise can be a cycloalkyl radical (spiro union), substitute for the oxindole skeleton in the 3-position. As alternatives, the spiro ring can contain heteroatoms, such as oxygen and nitrogen (optionally with substituents).
WO 95/18105 describes 1-phenylsulfonyl-1,3-dihydro-2H-indole-2-ones as ligands of the vasopressin receptors that have a nitrogen atom in the 3-

2
position. In addition, radicals, which can be alkyl, cycloalkyl, phenyl or benzyl radicals (each optionally with substituents), are bound in the 3-position.
Other publications, such as WO 01/55130, describe compounds that have nitrogen-containing rings (e.g., proline, homoproline, morpholine, tetrahydroisoquinoline or dihydroindole, each optionally with substituents) that are bound to the 3-position of the oxindole skeleton via their nitrogen atom, but that are substituted with phenylsulfonyl or phenyl groups (optionally with substituents) in both the 1-position and the 3-position on the oxindole ring.
In WO 03/008407, 1-phenylsulfonyl-oxindoles are described in which pyridylpiperazines are bound to the oxindole in the 3-position via an oxycarbonyl group and analogous functional groups.
The object of the present invention is to provide additional compounds for the treatment or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases, wherein these compounds display a high level of selective activity.
The object is solved by a compound or compounds having the general
formula (I),

where
A is Ce-10 aryl that can be substituted with a maximum of four residues
R4 that are selected independently of one another from the group consisting

3
of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)o-2-CN, CF3, OCF3, CONH2, CONH(CrC4 alkyl), CON(CrC4 alkyl)(CrC4 alkyl), NHCHO,
NHCONH2, N(C0-C4 alkylene)CONH2, N(C0-C4 alkylene)CONH(CrC4 alkyl), NHCOCH3, N02, (CH2)o-2-OH, O-d-Ce alkyl, (CH2)0-2-O-Ci-C4 alkyl, O-C0-C4 alkylene-phenyl, phenyl, CrC6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,
B is an aromatic or partly aromatic monocyclic or bicyclic Ce-io that can be substituted with the residues R6, R7, R8 and / or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)o-2-CN, CF3, OCF3, CONH2, CONH(d-C4 alkyl), CON(CrC4 alkyl)(CrC4 alkyl), NHCHO, N(QM alkylene)CONH(d-C4 alkyl), NHCOCH3, N02, OH, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-3-CH3, O-C0-C4 alkylene-phenyl, phenyl, d-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,
R1 is hydrogen, d-C6 alkyl, OH, 0-(Ci-C4 alkyl), N(CrC4 alkylXCi-C4 alkyl), CN, CONH2, OCF3, CF3, Br, F, CI, J, N02, NHCHO, NHCO(CrC4 alkyl) or NHCONH2,
R2 is hydrogen, C1-C4 alkyl, 0-(Ci-C4 alkyl), CI or F,
R3 is a residue (W)-(X)-(Y)-Z, wherein
W is d-C4 alkylene, (C0-C4 alkylene)-O-(C0-C4 alkylene) or (C0-C4
alkylene)-NR15-(C0-C4 alkylene), wherein R15 is hydrogen or C1-C4
alkyl,
X is CO, S02, (C=NH) or (C=N-CN) and
Y is a residue selected from the group consisting of

4

wherein Y can additionally be substituted with R10 and / or R11, and
R10 is hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, O-C1-C4 alkyl, O-C0-C4 alkylene-phenyl, NH2, NH(Ci-C4 alkyl) or N(CrC4 alkyl)(CrC4 alkyl),
R11 is hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, 0-CrC4 alkyl, O-C0-C4 alkylene-phenyl, NH2, NH(Ci-C4 alkyl) or N(Ci-C4 alkyl)(d-C4 alkyl), and
Z is a residue selected from the group consisting of

5


6
Furthermore, a compound or compounds with the general formula (I) are preferred wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4, which are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and CrCe alkyl,
B is a phenyl ring that can be substituted with the residues R6, R7, R8 and / or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and CrC6 alkyl,
R1 is hydrogen, CN, F; CI, C1-4 alkyl, OH or 0-(Ci.4 alkyl),
R2 is hydrogen,
R3 is a residue (W)-(X)-(Y)-Z, wherein
W is O, CH2NH, NHCH2> OCH2) CH20 or NH,
X is CO,
Z is a residue selected from the group consisting of
Y is a residue selected from the group consisting of


7

wherein Z can additionally be substituted with R12 and / or R13, wherein
R12 is hydrogen or C1-C4 alkyl,
R13 is hydrogen or C^CA alkyl and
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl.
Particularly preferred are a compound or compounds of the general formula (I), wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, 0-CrC4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and Ci-C6 alkyl,
B is a phenyl ring that can be substituted with the residues R6 and / or R7, wherein R6 and R7 can be selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl and C1-C6 alkyl,
R1 is hydrogen, F, CI, CH3, CN, CH2CH3, OCH3 or OCH2CH3,
R2 is hydrogen,
R3 is a residue (WHX)-OO-Z, wherein
W isO,CH2orNH,
X is CO,

8 Y is a residue selected from the group

wherein Z can be substituted with R12 and / or R13, wherein
R12 is hydrogen or C1-C4 alkyl,
R13 is hydrogen or C1-C4 alkyl and
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl.
Particularly preferred are furthermore compounds of the general formula (I), wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and d-Ce alkyl,
B is a phenyl ring that can be substituted with the residues R6 and / or R7, wherein R6 and R7 are selected independently of one
another from the group consisting of hydrogen, fluorine, chlorine, 0-
C1-C4 alkyl and d-Ce aJkyl,
R1 isCI,CH3,CN,CH2CH3orOCH3,

9
R2 is hydrogen,
R3 is a residue (W)-(X)-(Y)-Z, wherein
W is CH2, O or NH,
X is CO,
Y is a residue

wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl.
Furthermore, a compound or compounds with the general formula (I) are particularly preferred wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl and C1-C4 alkyl,
B is a phenyl ring that is substituted with the residues R6 and / or R7, wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl and C-i-Ce alkyl,
R1 is hydrogen, CI, CH3, CN, CH2CH3, OCH3 or OCH2CH3, R2 is hydrogen,
R3 is a residue (W)-(XMY)-Z, wherein W isCHt,OorNHf
X isCO,



10
Y is a residue
and Z is a residue
wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkynyl.
The expression "maximum of four residues R4" in connection with variable A means the presence of no, one, two, three or four substituents on A, wherein the residues R4 can be the same or different.
The expression "maximum of two residues R4" in connection with variable A means the presence of no, one or two substituents on A, wherein the residues R4 can be the same or different.
The expression "R10 and / or R11" in connection with variable Y means one or two identical or different residues selected from the group consisting of R10andR11.
The expression "R12 and / or R13" in connection w'th variable 7 m^n** one nr two identical or different residues selected from the group consisting of R12 and R13.
The variables that identify #te compounds of formula :(l) according to the invention have the following preferred meanings, independently of one another.

11
A is preferably a phenyl ring that can be substituted with a maximum of four
residues R4, even more preferably a phenyl ring that can be substituted with a maximum of two residues R4. In one embodiment, A is unsubstituted phenyl.
In another embodiment, A is substituted with a substituent. If A is substituted, the substituents R4 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)o-2-CN, CF3, OCF3, CONH2) CONH(CrC4 alkyl), CON(CrC4 alkyl)(Cr C4 alkyl), NHCHO, NHCONH2, N(C0-C4 alkylene)CONH2, N(C0-C4 alkylene)CONH(Ci-C4 alkyl), NHCOCH3, N02, (CH2)0.2-OH, O-d-Ce alkyl, (CH2)0-2-O-Ci-C4 alkyl, O-C0-C4 alkylene-phenyl, phenyl, Ci-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl, preferably hydrogen, chlorine, 0-CrC4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and C-i-C6 alkyl, even more preferably hydrogen, chlorine, O-C1-C4 alkyl and CrC4 alkyl. If A is a phenyl ring, a substituent is preferably to be found in the 2-position, wherein other substituents can be in the 3-, 4- or 5-position, or even more preferably, a substituent is located in the 2-position and a further one is located in the 3-, 4- or 5-position, and most preferably a substituent is located in the 2-position.
B is preferably a phenyl ring that can be substituted with the residues R6, R7, R8 and / or R9. Preferably, B is substituted with no, one, two, three or four identical or different residues selected from R6, R7, R8 and R9. More preferably, B is a phenyl ring that can be substituted with the residues R6 and / or R7. In one embodiment, B is unsubstituted phenyl. In another embodiment, B is substituted with a substituent R6. If B is substituted, the substituents R6, R7, R8 and / or R9 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine,
(CH2WCN, CF3, OCF3, CONH2, CONH(CrC4 alkyl), C0N(Gi-C4 aUcytXCr C4 alkyl). NHCHO, N(C
12
chlorine, O-C1-C4 alkyl, (CH2)o-2-0-{CH2)o-2-CH3 and Ci-Ce alkyl, and even more preferably hydrogen, fluorine, chlorine, 0-CrC4 alkyl and Ci-C6 alkyl. If
B is a phenyl ring, the substituents are preferably located in the 2-, 3-, 4-, 5-and / or 6-position, preferably there are a maximum of 4 substituents, of which two substituents are in the 2- and 4-positions or one substituent is either in the 2- or 4-position, and even more preferably, two substituents are in the 2- and 4-positions or one substituent is either in the 2- or 4-position.
R1 is preferably hydrogen, CN, F, CI, C1-4 alkyl or 0-(Ci-4 alkyl), even more preferably hydrogen, F, CI, CH3, CN, CH2CH3, OCH3 or OCH2CH3, and most preferably CI, CH3, CN, CH2CH3 or OCH3. R1 is preferably located in the 4-, 5- or 6-position, even more preferably in the 4- or 5-position, and most preferably in the 5-position.
R2 is preferably hydrogen.
R3 is a residue (W)-(X)-(Y)-Z, wherein preferred definitions of R3 result from the definitions of W, X, Y and Z, in which at least one of the definitions of W, X, Y and Z represents any preferred embodiment, as explained in the following. Preferably, all definitions of W, X, Y and Z represent any preferred embodiment. Most preferably, R3 is a residue (W)-(X)-(Y)-Z, wherein all definitions of W, X, Y and Z represent the most preferred embodiment in each case.
W is preferably O, (d-C4 alkylene)NH, NH(Ci-C4 alkylene), 0(C1-C4 alkylene), (C1-C4 alkylene)0 or NH, even more preferably O, CH2NH, NHCH2, OCH2, CH20 or NH, and most preferably CH2, O or NK. . - - *.
X is preferably CO or S02, most preferably CO.
Y is preferably

13

R10 is preferably hydrogen or C0-C4 alkyl, wherein the alkyl group can be in the 2-, 3-, 5- or 6-position, preferably hydrogen or a C1-C4 alkyl group that is in the 2-position and especially preferably hydrogen.
R11 is preferably hydrogen or C1-C4 alkyl, wherein the alkyl group can be in the 2-, 3-, 5- or 6-position, preferably hydrogen or a C1-C4 alkyl group that is in the 2-position and especially preferably hydrogen.
Z is preferably


In one embodiment, Z is
In another embodiment, Z is
14


R12 is preferably hydrogen or C1-C4 alkyl, wherein the alkyl group can be in the 2-, 3-, 4- or 6-position, preferably hydrogen or a C1-C4 alkyl group that is in the 2-position and especially preferably hydrogen.
R13 is preferably hydrogen or C1-C4 alkyl, wherein the alkyl group can be in the 2-, 3-, 4- or 6-position, preferably hydrogen or a CrC4 alkyl group that is in the 2-position and especially preferably hydrogen.
R14 is preferably hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, even more preferably hydrogen, CH3, CH2CH3, CH2CH2CH3 or CH(CH3)2, most preferably CH3.
R15 is preferably hydrogen or C1-C4 alkyl, preferably hydrogen, CH3, CH2CH3 or CH2CH2CH3, and most preferably hydrogen or CH3.
This results in the following especially preferred groups for R3:

15

Each of these preferred definitions of a variable can be combined with any definitions of the other variables.
Likewise especially preferred are the following compounds:
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-(2-methoxy-phenyl)-2,3-dihydro-1H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-chloro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
b-chloro-2-oxo-3-phenyl-2,3-dihydro-1H-indole-3-yl-ester]-dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidlne-4-yl)-piperazine-1 -carboxylic acid-[1 -{2,4-dimethoxy-benzenesulfonyl)-5-metnoxy-2-oxo-3-(2-methoxyphenyl)-2I3-dihydro-1 H-
indole-3-yl] ester dihydrochloride

16
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(Piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-fluoro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-bromo-2-
methyl-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
4-( 1 -Benzyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methyl-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-cyano-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4(1 -Methyl pipcridine-4-yl)-piperazine-1-carboxylicacid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(1 -Methyi-piperkline-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-Methyl-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yi] ester dihydrochloride
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-

17
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-indole-3-yl] ester dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(4-methoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(3,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-isopropyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-3-yl]
ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-benzene)-sulfonyl-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-
dihydro-1 H-indole-3-yl] ester dihydrochloride
4 (", -Methyl p';pcr:dine-4-y!)-piperazip.s-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yt)-piperazine-1 -carboxylic acid'(1 -(2-methyl-
betozenesitfonyl)-5HTiet^^ H-
indole-3-yl] ester dihydrochloride 4K1-Methyf-pip©rWine^yl)-piperazine-lKarboxyllcackt[H2-methyl^

18
benzenesulfonyl )-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(3-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-ethyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-
1H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2cxc-3-(2,3-dirr.othcxypher:y!)-2,3-d'!hydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
ber^enesulfonyl>^methox^2^xo-3K2,5Klimethoxyphwyl)-2l3^ihy^ H-indote-3-yl] ester dihydrochloride 4^1-Methyl-piperWine^yl>iiipefa2lne-lKarix)x^ acid*[1-(benzenesulfonyl)-5-m^rK>xy-2^xo-3K2,5-dimetrK>xyphenyl)-2,3HJihyd

19
1 H-indole-3-yl] ester dihydrochloride
-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-(2-methoxy-phenyl)-2,3-dihydro-1H-indole-3-yl] ester 4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-chloro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(Piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-fluoro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-
3-y!] sster
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyt-pipertdine-4-yl)-plpefazine-1 -carboxylic acid-[1 -{4-bromo-2-rnethyl-r^nzenesulfony1)-5-m^rK)xy-2^xch3-{2-metJiylptienyl>-2>3^ihydi^ 1H-indole-3-yl] ester dihydrochloride

20
4-( 1 -Benzyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methyl-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-cyano-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methyl-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-methoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(3,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-isopropyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-y!] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-iH-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-plperaztae-1 -carboxylic acid-[1 -(2,4-dimethoxy-benzenesulfonyl)-2-oxo-3-{2-methoxypheny1)-2,3-dihydro-1H-indole-3-yl]
ester dihydrochloride

21
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-benzene)-sulfonyl-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2)3-
dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2I3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(3-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
ir.dole 3-y!] cctcr dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-ethyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4^1-Methyl-piperkline-4-y1)-piDerazine-1 -carboxylic acid*[1-(2-methyl-benzenesulfonyl)-5-metrK)xy-2-oxo-3K2-propoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester dihydrochloride

22
4-(1 -Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1 -(2-methoxy-4-methyl-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2,5-dimethoxyphenyl)-2)3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2,5-dimethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -
(benzenesulfonyl)-5-methoxy-2-oxo-3-(2,5-dimethoxyphenyl)-2,3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-cyano-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2l3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-
1 H-indole-3-yl] ester
4-(1-Methyl-piperidine-4-y!)-p;pGrazinc 1 carboxylic acid [Ibenzenssulfonyl-
5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1 ^nzenesulforiyl)-5^loix>-2^xo-3H2^thoxypheny1)-2,3-dihydro-1 H-
indote-3-yl] ester
4-(1 -Methyl-piperidine-4-y1)-plperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1 -benzenesutfonyl)-5-chloro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1 H-

23
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-
1 H-indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4,6-trimethyl-
1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dichloro-1-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-
trifluoromethoxy-1-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-
2,3-dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-benzenesulfonyl-
5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
1-(2,4-Dimethoxy-1-benzenesulfonyl )-5-methoxy-3-(2-methoxyphenyl)-
3{2[(4-methyl-piperidine-1 -yl)-piperazine-1 -yl]-2-oxo-ethoxy}-1,3-
dihydroindolone dihydrochloride
1 -(2,4-Dimethoxy-1 -benzenesulfonyl)-5-methoxy-3-(2-methoxypheny1)-
3{2[(4-methyl-piperazine-1 -yl)-piperidine-1 -yl]-2-oxo-ethoxy}-1,3-
dihydroindolone
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2)3-dihydro-1H-
indcle-3 yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-1 -
benzenesulfonyl)-5-methoxy-2-oxo-3-[2-(2-methoxyethyl)phenyl]-2>3-
dihydro-1 H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-plperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-1-rjenzenesulfonyl)-5^etlH)xy-2^xo-3-[2^2-m0thoxyemy1)prmr^
2,3-dihydro-1H-indole-3-yl] ester dihydrochloride

24
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-1-benzenesulfonyl)-5-methoxy-2-oxo-3-[2-(2-methoxyethyl)phenyl]-2,3-
dihydro-1H-indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-213-clihydro-
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
1-benzenesulfonyl )-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dichloro-1 -
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] amide dihydrochloride
4 (1 M3thy!-piperidine-4-yl)-piperazine-1-carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
4^14AethyH»peridine^ylH)ipera3^
14>©rizinesulfw^)-5^toio-2 indole-3-y 4-(1 -Methyl-pipertdine-4-yl)-pipera2ine-1 -carboxylic aci4-[1 -(4-teopropyl-1 -

25
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-cyano-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-benzenesulfonyl-
3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[3-(2-
isopropoxyphenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-
dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1-(4-
methoxy-benzenesulfonyl)-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-{5-methoxy-1 -(2-
rr.Gthcxy-benzenes,j|fony!)-3-[2-(2-methoxy-ethyl)-nhenyl]-2-oxo-2,3-dihydro-
1 H-indole-3-yl}-amide dihydrochloride
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1 -(2-
methoxy-benzenesulfonyl)-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1H-
indole-3-yl] ester
4^1-Methyl-piperidine^yl)-pipera2ira^^
phenyl)-5-methoxy-1 -(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-

26
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1 -(4-
methoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-isopropoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-isopropoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-isopropoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indcle-3-y!] estsr
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Methyl-piperazine-1 -yl>-jrfperidine-1 -carboxylic acid-[5-chloro-1 -(2,4-
dimethoxy-benzenesutfonylW2^thoxy-phenyl)-2K)XO-2,3Klihytlro-1H-
indole-3-yl]-ester

27
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-benzenesulfonyl)-3-(2-methoxy-phenyl)-2-oxo-6-trifluoromethyl-213-dihydro-
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-fluoro-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-f!uoro-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-cyano-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[5-chloro-1-(2-
methoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2I3-dihydro-1H-
indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3-dihydro-
1 H-indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2)3-dihydro-1H-indole-
3-yl] amide dihydrochloride
4-(4-Methyl-piperazine-1 -y1)-piperidine-1 -carboxylic acid-[5-chtoro-1 -(2,4-
dimethoxy-benzenesulfonylW2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-
indole-3-yl] amide dihydrochloride

28
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-2-oxo-1 -(toluene-2-sulfonyl)-2,3-dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-2-oxo-1 -(toluene-4-sulfonyl)-2,3-dihydro-1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-chloro-
benzenesulfonyl)-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-1 -(2,5-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2)3-dihydro-1H-
indole-3-yl] ester
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[5-cyano-1-{2-
cyano-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[5-cyano-1-(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-indole-3-
yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-l5-cyano-3-(2-
ethoxy-phenyl)-1-(4-isopropyl-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-pheny!)-1-(2-fluoro-benzenesulfonyl)-2-oxo-2I3-dihydro-1H-indole-3-
yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-1 -[5-chloro-2-methoxy-benzenesulfbny1)-5K)yarK)-3^2^thoxy-phenyl)-2^xor2,3^
1H-indole-3-yll ester
4-(1 -Methyl-plperidine-4-yl)-piperazine-1 -carboxylic add-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-5-methyl-benzenesulfonyl)-2-oxo-2I3-dihydro-

29
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-4-methyl-benzenesulfonyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3- ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-(4-acetylamino-
benzenesulfonyl)-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-methoxy-
bcrizcncs'jlfcnyl) -3-(2 9thoxy-phenyl)-5-f!uoro-2-oxo-2,3-dihydro-1 H-indole-
3-yl] amide dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-isopropyl-1 -(2-methoxy-benzenesulfonyl>-2-oxo-2,3-dihydro-1 H-
indole-3-yl] ester
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic add-{5-cyano-3-(2-
ethoxy-phenyl)-1 -(2-methoxy-benzenesulfonyl)-2-oxo-2f 3-dihydro-1 H-indole-

30
3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-fluoro-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-isopropyl-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
(-)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
(+)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
(-)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
(+)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
3-(2-ethoxy-phenyl)-5-isopropyl-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(1-M8thyl-pip3ridir.c-/! y!) piperazine-1-carboxylic gcid-[4-chloro-3-(2-
methoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic ackH4-chloro-3-{2-
methoxy-phenyl>1K4-methoxy-benzenesutfbnyl)-2K5xo-23 indole-3-yl]-ester
4-(1 -Methyl-piperazine-4-yl)-p}peridine-1 -carboxylic acki-[3-(2-ethoxy-

31
phenyl )-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] amide dihydrochloride
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[6-chloro-3-(2-
methoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-isopropyl-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-Piperidine-4-yl-piperazine-1 -carboxylic acid-[5-cyano-1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
ester dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-ethyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-
phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
4-(4-propyl-piperidine-1-yl)-piperazine-1 -carboxylic acid-[5-cyano 3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2I3-dihydro-1H-
indole-3-yl] ester
4-(4-isopropyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1 -(2,4-dimethoxy-benzenesulfonyl>-2-oxo-2,3-dihydro-1 H-
indole-3-yl] ester
4-(4-Methyl-piperidine-1 -yl)-piperazirte-1 -carboxylic acid-[4-methyl-3-(2-

32
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(3,4-dibromo-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[4-methoxy-3-(2-
methoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[4-methoxy-3-(2-
methoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-methoxy-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-Piperazine-1 -yl-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide dihydrochloride
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
4-(4-Propyl-pipcrazine-1 -yl) piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dlhydro-1 H-
indole-3-yl] amide dihydrochloride
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-

33
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
4-(4-Propyl-piperazine-1-yl)-piperidine-1-carboxylicacid-[5-cyano-1-
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indote-
3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dif!L:crobenzGnsculfony!)~3-(2-ethoxy-ph9ny!)-2-oxo-2,3-dihydro-iH-indole-
3-yl] ester dihydrochloride
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-pheny1)-2-oxo-2,3-dihydro-1H4ndote-3-
yl] ester
4-(4-Methyl-piperazlne-1 -yl)-piperidtne-1 -carboxylic adcK5-cyano*1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-irKlole-

34
3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
4-(4-Propargyl-3-yl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
(4-methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-Allyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-«ndole-
3-yl] ester
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-fluoro-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-indole-3-yl]
amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide

35
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2I3-dihydro-1H-
indole-3-yl] amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
4-(4-lsopropyl-piperazine-1-yl)-piperidine-1-carboxylic acid-[5-cyano-1-(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
3-(2-Ethoxy-phenyl)-1-benzenesulfonyl-2-oxo-3-{2-oxo-2-[4-(4-propyl-
piperazine-1 -yl)-piperidine-1 -ylJ-ethyl^.S-dihydro-l H-indole-5-carboxylic-
acid nitrile
3-(2-Ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dlhydro-1 H-indole-5-
carboxyllc-acid nitrile 3-(2-Ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -y1)-piperkline-1 -y0-ethyi}-2,3-dihydro-1 H-indole-5-carboxytic-acid nitrile

36
3-(2-Ethoxy-phenyl)-1-(2-fluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrite
3-(2-Ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-
(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrite
3-(2-Ethoxy-phenyl)-1-(2,4-difluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
3-(2-Ethoxy-phenyl)-1-(4-chloro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2)3-dihydro-1H-indole-3-
yl] amide
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydrc~1H-indole-
3 yl] amide
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
4-(4-Ethyl-piperazJne-1-yl)-pirjerWine-1-(»rboxyiicacid-[5-cyan6-1-(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2l3-dihydro-1H-indole-
3-yl] amide

37
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-fluoro-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-indole-3-yl]
amide
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-(4-methoxy-1-
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
4-(4-lsopropyl-piperazine-1-yl)-piperidine-1 -carboxylic acid-[5-cyano-1-(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
3-(2-Ethoxy-phenyl)-1-(4-fluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
their tautomeric, enantiomeric and / or diastereomeric forms, and their prodrugs, as well as non-salt forms and other physiologically compatible salts of the compound or compounds according to the invention.
The compound or compounds according to the invention can be present as racemates or as enantiomerically-pure or diastereomerically-pure compounds. Preferably, the compounds are present as enantiomerically-pure or diastereomerically-pure compounds.
Physiologically compatible salts can be formed, for example, with the
following aniens:
Chloride, bromide, phosphate, carbonate, nitrate, perchlorate, sutfate, citrate, lactate, tartrate, mateate, fumarate, mandelate, benzoate, ascorbate, clnnamate, glycolate, methanesulfonate, formate, malonate, naphthalene-2-sulfonate, tosylate, salicylate and / or acetate. Further suitable acids are, for example, listed in 'Fortschritte der Arzneimittelforschung", 1966, Birkhauser

38
Publishing House, Vol. 10, pp. 224-285.
In the context of the present description, the terms "alky!" and "alkylene"
always comprise unbranched and branched "alkyl" or "alkylene".
In the context of the description, CrC4 alkyl is preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl ort-butyl.
In the context of the description, C0 alkylene or (CH2)o indicates a single bond.
In the context of the description, C1-C4 alkylene is methylene, ethylene or branched or unbranched propylene or butylene.
In the context of the description, CrC6 alkyl is methyl, ethyl or branched or unbranched propyl, butyl, pentyl or hexyl, preferably C1-C4 alkyl, i.e., methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl ort-butyl.
In the context of the description, Ci-C6 alkylene is methylene, ethylene or branched or unbranched propylene, butylene, pentylene or hexylene, preferably CrC4 alkylene, i.e., methylene, ethylene or branched or unbranched propylene or butylene.
The symbol in the chemical formulas for Y and Z shows the
positions of attachment of Y to X and Z and the positions of attachment of Z to Y. In the formulas for Y, each position of attachment can represent a bond toXorZ.
The compounds according to the invention are effective after administration in various ways, particularly orally.
The compounds according to the invention show good affinity to vasopressin receptors, for example, the subtype Via and V1b vasopressin receptors.

39
Because the various vasopressin receptors impart very different effects of the vasopressin (M. Thibonnier, Exp. Opin. Invest. Drugs 1998, 7(5), 729-740; Serradeil-Le Gal, C, et al.; Prog Brain Res. 2002; 139:197-210), it is especially significant to obtain effects selectively, for example, on one vasopressin receptor, in order in this way to achieve the desired effect without simultaneously causing significant side-effects. For example, vasopressin produces effects on the kidney and its function via the receptor V2, which would be undesirable in the case of possible treatment of CNS diseases. Consequently, in addition to the actual affinity at the target receptor, the selectivity with respect to the other vasopressin receptors is also particularly significant. The compounds according to the invention display the advantage of having very good affinities to the desired receptors, such as vasopressin receptors V1b and Via, while simultaneously having improved selectivity with respect to the other receptors, such as V2.
The present invention also provides the application of the compounds according to the invention for treatment and / or prophylaxis of diseases in which the progress of the disease depends at least partially on vasopressin, i.e., diseases that show an elevated vasopressin or oxytocin level, which can directly or indirectly contribute to the clinical picture.
Furthermore, the present invention provides the application of compounds according to the invention for the treatment and / or prophylaxis of diseases, such as diabetes insipidus, nocturnal enuresis, incontinence and diseases in which coagulation disorders occur, and / or for the delay of micturition.
The present invention also provides the application of the compounds according to the invention for treatment and / or prophylaxis of the following diseases: hypertension, pulmonary hypertension, cardiac insufficiency, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, oedemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome,

40
disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and peptic ulcer, emesis, recurrent emesis during chemotherapy and travel sickness.
The compounds according to the invention can also be used for the treatment of various vasopressin-dependent or oxytocin-dependent complaints that have central nervous system causes or changes in the HPA (hypothalamic pituitary adrenal) axis, for example in case of affective disorders such as depressive disorders and bipolar disorders. Examples in this group are dysthymic disorders, phobias, post-traumatic stress disorders, general anxiety disorders, panic disorders, seasonal depressions and sleep disorders.
Likewise, the compounds according to the invention can be used in the treatment of anxiety disorders and stress-related anxiety disorders, such as, for example, generalised anxiety disorders, phobias, post-traumatic anxiety disorders, panic anxiety disorders, obsessive-compulsive anxiety disorders, acute stress-related anxiety disorders and social phobia. Furthermore, the compounds according to the invention can also be used in the treatment of memory disturbances, Alzheimer disease, psychoses, psychotic disorders, sleep disorders and / or Cushing syndrome.
The present invention also relates to pharmaceutical compositions that contain an effective dose of a compound according to the invention or of a pharmaceutically compatible salt thereof and suitable excipients.
These excipients are selected according to the pharmaceutical form and the desired form of application.
The compounds of general formula I according to the invention or, where applicable, suitable salts of these compounds, can be used for the production of pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal,

41
transdermal or rectal administration, and can be administered to animals or humans in standardised forms of administration, mixed with conventional pharmaceutical excipients, for the prophylaxis or treatment of the abovementioned disorders and diseases.
The suitable standardised forms of administration include forms for oral administration, such as tablets, gelatine capsules, powder, granules and solutions or suspensions for oral intake, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms for subcutaneous, intramuscular or intravenous administration and forms for rectal administration.
The compounds according to the invention can be used in creams, ointments or lotions for topical administration.
In order to achieve the desired prophylactic or therapeutic effect, the dose of the basic active constituent can vary between 0.01 and 50 mg per kg body weight per day.
Each single dose can contain 0.05 to 5,000 mg, preferably 1 to 1,000 mg, of the active constituent in combination with a pharmaceutical excipient. This single dose can be administered 1 to 5 times a day, so that a daily dose of 0.5 to 25,000 mg, preferably 1 to 5,000 mg, is administered.
If a solid composition in the form of tablets is prepared, the principal constituent is mixed with a pharmaceutical excipient, such as gelatine, starch, lactose, magnesium ctcaratG, talc, silicon dicxide or the like.
The tablets can be coated with sucrose, a cellulose derivative or another suitable substance or otherwise treated in order to obtain sustained or delayed activity and in order to obtain continuous release of a predetermined
quantity of the basic active constituent.

42
A preparation in the form of gelatine capsules is obtained by means of mixing the active constituent with an extender and incorporating the resulting mixture into soft or hard gelatine capsules.
A preparation in the form of a syrup or elixir or for administration in the form of drops can contain active constituents together with a sweetener that is preferably calorie-free, methylparaben or propylparaben as an antiseptic, a flavouring agent and a suitable colouring substance.
The water-dispersible powders or granules can contain the active constituents, mixed with dispersion agents, wetting agents or suspending agents, such as polyvinylpyrrolidones, as well as sweeteners or taste correctors.
Rectal administration is achieved by means of the use of suppositories that are prepared with bonding agents that liquefy at rectal temperature, for example, cocoa butter or polyethylene glycols. Parenteral administration is effected by the use of aqueous suspensions, isotonic saline solutions or sterile and injectable solutions that contain pharmacologically well-tolerated dispersion agents and / or wetting agents, such as propylene glycol or polyethylene glycol.
The basic active constituent can also be formulated as microcapsules or centrosomes, where suitable, with one or more excipients or additives.
In addition to the compounds of the general formula (I) or their pnarmaoeutiv^ny - weil-iCieratcd salts, the compositions according tc the invention can contain other basic active constituents that can be useful for treatment of the abovementioned disorders or diseases.
The present invention consequently furthermore relates to pharmaceutical compositions in which a number of basic active constituents are present together, wherein at least one of these is a compound according to the

43
invention.
The compounds according to the invention represent antagonists of the so-called receptors of the vasopressin-oxytocin family. Compounds of this type can be examined in suitable tests that determine the affinity to a receptor, wherein the affinity constant Ki represents a measure of the potency for bonding to the receptor of the compounds, with a smaller value representing greater potency. The compounds according to the invention are, for example, tested for their receptor affinity in the following vasopressin receptor subtype V1 b receptor.

44
Vasopressin Via receptor binding test
The substances were dissolved in DMSO in a concentration of 10"2 M and further diluted in DMSO to 10"3 M to 10"9 M. These DMSO solutions were diluted 1:10 with a test buffer. In the test batch, the substance concentration was again diluted 1:10.
The binding test was conducted according to the method of Tahara et al. (Tahara A. et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)). In the test batch (0.250 ml), membranes (50 ug protein in an incubation buffer (50 mmol tris, 10 mmol MgCI2, 0.1% BSA adjusted to pH 7.4 with HCI)) of CHO cells were incubated with stably expressed human Via receptors (preparation Via clone 5.0, with protease inhibitors, Roche complete Mini # 1836170) with 0.04 nmol 125 iodine AVP (NEX128) in the incubation buffer (total binding) or additionally with increasing concentrations of the test substance (displacement experiment). The non-specific binding was determined with 10"6 M AVP. Determinations were carried out three times.
After incubation, 60 minutes at room temperature, the free radioligand was filtered off using vacuum filtration (Skatron cell harvester 7000) through
Wathman GF/B fibreglass filters, and the filters were transferred to scintillation containers.
The liquid scintillation measurement was made in a Tricarb device, model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out with the help of a standard quench series.
The binding parameters were calculated using non-linear regression in SAS. The algorithms of the program work in a manner analogous to the LIGAND evaluation program (Munson PJ und Rodbard D, Analytical Biochem. 107, 220-239(1980)).
For the examples according to the invention, the affinities to the human

45
vasopressin receptor V1b were measured and affinity constants were determined in the above test. The examples 1, 3, 4, 5, 8 and 13 here
showed Ki values under 100 nmol.
Vasopressin V1b receptor binding test
The substances were dissolved in DMSO in a concentration of 10~2 M and further diluted in DMSO to 10"3 M to 10"9 M. These DMSO solutions were diluted 1:10 with a test buffer. In the test batch, the substance concentration was again diluted 1:10.
The binding test was conducted according to the method of Tahara et al. (Tahara A. et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)). In the test batch (0.250 ml), membranes (58 ug protein in an incubation buffer) of CHO-K1 cells were incubated with stably expressed human V1b receptors (preparation V1b-3H2, with protease inhibitors, Roche complete Mini # 1836170) with 1.5 nmol 3H-AVP (8-Arg-Vasopressin, NET 800) in incubation buffer (50 mmol Tris, 10 mmol MgCI2, 0.1% BSA adjusted to pH 7.4 with HCI) (total binding) or additionally with increasing concentrations of the test substance (displacement experiment). The non-specific binding was determined with 10"6 M AVP. Determinations were carried out three times.
Incubation buffer: 50 mmol tris, 10 mmol MgCl2, 0.1% BSA adjusted to pH 7.4 with HCI.
Aftsr incubation, 60 minutes at room temperature, the free radioligand was filtered off using vacuum filtration (Skatron cell harvester 7000) through Wathman GF/B fibreglass filters, and the filters were transferred to scintillation containers.
The liquid scintillation measurement was made in a Tricarb device, model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm

46
was carried out with the help of a standard quench series.
The binding parameters were calculated using non-linear regression in SAS. The algorithms of the program work in a manner analogous to the LIGAND evaluation program (Munson PJ und Rodbard D, Analytical Biochem. 107, 220-239 (1980)).
For the examples according to the invention, the affinities to the human vasopressin receptor V1 b were measured and affinity constants determined in the above test. The examples 2, 6, 10, 16, 17, 23, 24, 26 and 30 here showed Ki values under 100 nmol.
Effect on vasopressin-induced calcium rise in cells that carry a cloned human vasopressin receptor
The functional activity of the test substances was examined on CHO-K1 cells that were transfected in a stable manner with the human V1b receptor. 50,000 cells were sown in each well of a microtitre plate with 96 wells and incubated in a culture medium overnight at 37° C in a saturated steam atmosphere with 5% CO2. The culture medium consisted of DMEM/Nut Mix F12 with Glutamax I (Invitrogen), 10% foetal calf serum, 100 units/ml penicillin, 100 ug/ml streptomycin and 800 ug/ml Geneticin. The next day, the cells were washed with culture medium and loaded with a fluorescent dye for calcium according to the manufacturer's information (Ca++-Plus Assay Kit, Molecular Devices). The cells were loaded in the presence of probenecid (1% by vol). The tect substancss were dil'jted with culture medium (end concentration 10"10 to 10"5 M) and incubated at room temperature for 15 minutes with the cells, which were loaded with dye. Subsequently, Arg-vasopressin (10"8 M) was added and the maximum
fluorescence signal was determined with a FLIPR-96 measuring tool (Molecular Devices). Concentration effect curves were prepared with nonlinear regression algorithms (GraphPad Prism 3.0). Kb values were

47
calculated from IC50 values according to Cheng and Prusoff (Kb = IC50 /1 + L / EC50).
In the following, synthetic pathways for the production of the compounds according to the invention are described by way of example.
The production of the oxindoles according to the invention can follow various pathways; this is sketched in the Synthesis Diagrams 1-4. In these synthesis diagrams, the variables have the same meaning as in the general formula (I).

Starting with compounds A-H or A-Br or A-CI, which are metalated in the customary way, such as, for example, the Grignard compound (Mg) or

48
organyllithium compound, the 3-hydroxy-oxindoles III can be obtained by adding isatin II. The metalated compounds can be obtained in the customary way from halogen or hydrocarbon compounds. Example instructions are contained in Houben-Weil, Methoden zur Organischen Chemie, Vol. 13,1-2, Chap. "Mg- bzw. Li-Verbindungen". The isatins II are either available commercially or were produced using methods analogous to those described in the literature (Advances in Heterocyclic Chemistry, A.R. Katritzky and A.J. Boulton, Academic Press, New York, 1975, 18, 2-58; J. Brazil. Chem. Soc. 12, 273-324, 2001).
The 3-hydroxy-oxindoles III can be converted into the compounds IV, which carry a volatile group LG in the 3-position, wherein the volatile group LG can be customary leaving groups, such as halogenides, mesylate or tosylate. Consequently, for example (LG = chlorine), the intermediate product IV can be produced by treating the alcohol III with thionyl chloride in the presence of a base, such as pyridine, for example. Alternatively, alcohols III can be obtained by conversion into the mesylate by means of methane sulfonyl chloride in the presence of a base, such as triethylamine, for example. The compounds IV are subsequently reacted with amines NH2R15, wherein the analogous amines V are obtained. For example, substitution reactions of that kind with amines in the presence of a base such as N,N-diisopropylethylamine can result in the analogous 3-amino-oxindoles V. V can subsequently result in DMF from treatment with sulfonic acid chlorides VI after deprotonation with a strong base, such as potassium-te/f-butylate or sodium hydride, and be converted into the product VII. In an analogous way, starting with the alcohols III, the corresponding derivatives VII with Q = O can be obtained.

49

To produce the compounds XIII according to the invention, the oxindoles Ilia are first converted with sulfonic acid chlorides XI under the conditions already described above. The sulfonic acid chlorides used can be purchased or they can be produced in a way analogous to the known methods (see e.g. J. Med. Chem. 40, 1149 (1997)). The compounds XIII according to the invention are produced in various ways, starting with the sulfonated compounds XII: (i) reaction with carbamoyl chlorides Z-Y-CO-CI in the presence of a base, such as triethylamine; (ii) activation with chlorocarbonic acid phenylester in the presence of a base, such as pyridine and subsequent reaction with amines Z-Y-H, where necessary at a raised temperature. The amines Z-Y-H can be purchased or they can be produced according to methods known in the literature.
The production of the compounds XXII according to the invention, which carry a functionalised nitrogen atom in the 3-position (e.g., amides, sulfonamides, carbamates and ureas) takes place in a manner analogous to that shown in Synthesis Diagram 2: the 3-amino-oxindoles XII (Q = NR15) are converted into the compounds XIII according to the invention by means of reaction with reagents for the derivatization of amino groups, such as carboxylic acids, carboxylic acid chlorides, carboxylic acid anhydrides, sulfonic acid chlorides, chloroformates, isocyanates or carbamoyl chlorides, wherein generally customary methods are used (see J. March, Advanced Organic Chemistry, 1992, 4th edition., Wiley, New York, p. 417-421; 499; 903). Furthermore, the 3-amino group in the compounds XII (Q= NH) can be

50
substituted by treatment with alkylation means, such as alkyl bromides, iodides or mesylates, as well as by reaction with aldehydes or ketones in the presence of reducing agents, such as sodium cyanoborohydride, in the sense of a reductive amination (J. March, Advanced Organic Chemistry, 1992, 4th edition., Wiley, New York, p. 411; 898).
Alternatively, the structural elements XII can be produced according to the two-stage method shown in Synthesis Diagram 3.

Sulfonated isatins XV are obtained by means of deprotonation of isatins II with a strong base, such as sodium hydride or potassium-tert-butanolate, followed by treatment with sulfonic acid chlorides XI. The compounds XIla are obtained in the second step by the addition of metalated compounds I to the 3-keto group of the sulfonyl-isatins XV. The instructions are analogous to the above-described methods.

51

In Synthesis Diagram 4, pathways to compounds in which W can be varied are sketched. Alcohols III are reacted to the derivatives XXIV with haloacid esters, wherein preferably bromides and chlorides are used, but analogous mesylates or tosylates and similar compounds in which a nucleofuge is present can also be used. The reactions can be carried out in polar solvents, for example, such as DMF or THF, with the addition of basic substances, such as, for example, NaH, potassium-tert-butanolate, sodium ethanolate, trialkylamines or potassium carbonate, at room temperature or at a raised

52
temperature, such as the boiling temperature of the solvent. The reaction of the indole-2-one XXIII to XXIV is carried out in an analogous manner. The indolones XXIII can be synthetically produced, either from the analogous alcohols III by reduction of the alcohol group, for example, with triethylsilane or in a manner analogous to Mullock, E.B. et al., J. Chem. Soc. C, 1970, 6, 829-833, Ghosal, S. et al., Ind. J. Chem., 1969m 7, 1095-1097 and US 2,759,935. The esters XXIV can be converted into the analogous carboxylic acids XXV with acids, such as HCI and H2SO4, or bases, such as NaOH, KOH or LiOH, wherein solvents are normally used, such as alcohols or THF, with the addition of aqueous acids or bases, at room temperature or at temperatures from 25 - 70° C. These acids XXV can be converted into the derivatives XXVI by means of reacting the acids with, for example, amines, using customary coupling conditions, as they are cited in, for example, R.C. Larock, Comprehensive Organic Transformations, Wiley 1999, Chap. 9. The introduction of the sulfonic acid residue B-SO2" takes place in a manner analogous to that described above. Alternatively to Diagram 4, the last two steps can also be carried out in the reverse order.

53
EXPERIMENTAL SECTION
Example 1
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-(2-methoxy-phenyl)-2,3-dihydro-1H-indole-3-yl] ester
1 a) 5-chloro-3-hydroxy-3-(2-methoxyphenyl)-indole-2-one 40 g (1.65 mol) magnesium shavings were overlaid with 100 ml ether, and after the addition of a small amount of iodine, they were carefully heated until the reaction kicked off. 203 ml (1.65 mol) bromanisole, dissolved in 450 ml ether, were dropped in to the boiling solution so slowly that the reaction continually proceeded at a low boil. Subsequently, with slight cooling to 20° C, 75 g (0.41 mol) 5-chlorisatin in 750 ml water-free tetrahydrofurane were added in by drops. After this, everything was stirred for 30 minutes more at room temperature. The reaction solution was poured into an aqueous NH4CI solution while being stirred. This aqueous phase was extracted a number of times with ethyl acetate and the combined aqueous phases were washed with water four times, dried and concentrated in a vacuum. The residue obtained was crystallised from isopropanol, wherein 106 g of the intermediate product resulted.
1 b) 5-chloro-1 -(2,4-dimethoxy-benzenesulfonyl)-3-hydroxy-3-(2-2-
methoxy-phenyl)-indole-2-one
2 g (18.1 mmol) potassium-tert.-butanolate were added in portions to 5 g
(17.3 mmol) of the intermediate product 1a in 50 ml water-free
dimethylformamide and everything was stirred for approximately 60 minutes.
Then 3.2 g (18.1 mmol) benzene sulfonic acid chloride were rapidly added
by drops at 0° C. This was then stirred for 2 h at 0° C and then for 16 h at
room temperature. The reaction solution was subsequently poured on to 250
ml icy water/K2C03 solution, wherein a precipitate arose that was dissolved in methylene chloride. This organic phase was washed with NaCI solution, dried and concentrated in a vacuum. The residue obtained was crystallised

54
from ethanol, wherein 2.8 g of the intermediate product were obtained.
1 c) Carbonic acid-[5-chloro-1-(2,4-dimethoxy-benzenesulfonyl)-3-(2-
methoxy-phenyl)-2-oxo-2,3-dihydro-1 -H-indole-3-yl] ester-phenyl ester 3.3 g (7.7 mmol) of the intermediate product 1b and 4.65 g (46 mmol) triethylamine were dissolved in 30 ml methylene chloride. 4.2 g (26.9 mmol) chloroformic acid phenyl ester were rapidly added by drops at 0° C. This was stirred for 15 minutes more and then the reaction solution was poured into a 5% mixture of potassium carbonate solution and icy water. The aqueous solution was extracted with methyl chloride three times. The combined organic phases were washed with aqueous potassium carbonate solution and an NaCI solution, dried over MgS04 and concentrated in a vacuum. The residue obtained was treated with a small quantity of methanol, wherein a solid precipitated that was isolated and dried. 3.2 g of the intermediate product were obtained.
1 d) 4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-5-chloro-2-oxo-3-(2-methoxy-phenyl)-2,3-dihydro-1H-indole-3-yl] ester
0.15 g (0.27 mmol) of the intermediate product 1c and 204 mg (1.1 mmol) 1-methylpiperidine-4-yl)-piperazine were mixed for 16 h at room temperature in 5 ml tetrahydrofurane. Then the solvent was removed in a vacuum. The residue was crystallised from 5 ml methanol, wherein 95 mg of the product were obtained.
1H-NMR (De-DMSO): 8 = 1.35(2H), 1.6(2H), 1.8(2H), 2.1 (3H), 2.15(1 H), 2.3(2H), 2.75(2H), 3.05(2H), 3.3(3H), 3.4-3.7(1H), 6.9(1H), 7.1(1H), 7.15(1H), 7.35C!H), 7.45(1H), 7.S5(2H), 7.7-7.9(2H) and 8.1(2H) ppm.
Example 2
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1-(2,4-dimethoxy-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-

55
indole-3-yl] ester
2a) 5-Chloro-3-hydroxy-3-(2-propoxyphenyl)-indole-2-one 3.1 g (0.13 mol) magnesium shavings were overlaid with 20 ml ether, and after the addition of a small quantity of iodine, they were carefully heated until the reaction kicked off. 27.3 g (0.13 mol) 2-propoxy-1-bromobenzene dissolved in 100 ml ether were dropped in to the boiling solution so slowly that the reaction continually proceeded at a low boil. Subsequently, with slight cooling to 20° C, 7.5 g (42 mmol) 5-methoxisatin in 150 ml water-free tetrahydrofurane were added in by drops. After this, everything was stirred for 30 minutes more at room temperature. The reaction solution was poured into an aqueous NH4CI solution while being stirred. This aqueous phase was extracted a number of times with ethyl acetate and the combined aqueous phases were washed with water four times, dried and concentrated in a vacuum. The residue obtained was crystallised from a small quantity of ethyl
acetate, wherein 8.3 g of the intermediate product resulted.
2b) Carbonic acid-[5-methoxy-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1 -H-indole-3-yl] ester-phenyl ester
1.26 ml (10.1 mmol) chloroformic acid phenyl ester were rapidly added to 3 g (9.6 mmol) of the intermediate product 2a in 50 ml pyridine at 0° C. This was then stirred for 16 h at room temperature. Subsequently, everything was poured into icy water and extracted with ethyl acetate a number of times. The combined organic phases were washed a number of times with water, dried over MgSC*4 and concentrated in a vacuum. The residue obtained was treated with a little ether, wherein a solid precipitated that was isolated and dried. 3.4 g of the intermediate product were obtained.
2c) 4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-methoxy-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1 H-indole-3-yl] ester 3.3 g (7.6 mmol) of the intermediate product 2b and 5.6 g (30.5 mmol) 1-methylpiperidine-4-yl)-piperazine were stirred for 16 h at room temperature in 100 ml tetrahydrofurane. Then the solvent was removed in a vacuum. The residue was distributed between water and ethyl acetate. The water phase

56
was then washed with ethyl acetate twice. The combined ethyl acetate phases were washed again with water, dried and concentrated in a vacuum. The residue was mixed with ether by stirring, wherein a solid resulted that was isolated. 2.9 g of the intermediate product were obtained.
2d) 4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
54 mg (0.48 mmol) of potassium-tert.-butanolate were added in portions to 200 mg (0.38 mmol) of the intermediate product 2c in 5 ml water-free dimethylformamide and everything was stirred for approximately 60 minutes. Then 113 mg (0.48 mmol) 2,4 dimethoxybenzene sulfonic acid chloride were rapidly added by drops at 0° C. This was then stirred for 16 h at room temperature. The reaction solution was subsequently poured on to 1 M NaOH, wherein a precipitate formed that was isolated. This precipitate was dissolved in 1 ml methanol and charged with 1 ml ethereal HCI. This solution was kept overnight at 0° C, wherein a precipitate resulted that was isolated. 213 mg of the product were obtained as dihydrochloride. 1H-NMR (De-DMSO): 8 = 0.7(3H), 1.5(2H), 2.0(2H), 2.3(2H), 2J(3H), 2.8-3.7(18H), 3.8(2H), 3.85(3H), 4.3(1 H), 6.6(3H), 6.0-7.1 (3H), 7.35(1 H), 7.7(2H), 7.85(1 H) and 10.4-10.8(N+H, broad) ppm.
Example 3
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyO-S-chloro^-oxo-S^-methoxyphenyl^.S-dihydro-IH-
indole-3-yl] amide dihydrochloiide
3a) 3,5 Dichloro-3-(2-methoxyphenyl)-indole-2-one
38 ml (0.518 mol) thionyl chloride were slowly added by drops to 100 g (0.345 mol) of the intermediate product 1a, 56 ml (0.695 mol) pyridine in 1 I methylene chloride at 0° C, and then stirred for approximately 30 minutes

57
more. Then the reaction mixture was poured on to icy water and the organic phase was separated. This organic phase was then washed with water, dried and concentrated in a vacuum. The residue was treated with toluene a number of times and the organic solvent was removed in a vacuum each time. 79 g of the raw product were obtained and further reacted without further cleaning.
3b) 3-Amino-5-chloro-3-(2-methoxyphenyl)-indole-2-one
10 g (32.45 mmol) of the intermediate product 2a were suspended in 100 ml
methylene chloride. After the addition of 100 ml 2-molar ethanol ammonia solution, the reaction mixture was stirred for 16 h. After this, everything was poured on to icy water and the organic phase was separated. The aqueous phase was cooled, wherein a white crystallizate formed, which was isolated. 5.7 g of the product were obtained.
3c) Carbonic acid-[5-chloro-2-oxo-3-(2-methoxy-phenyl>-2,3-dihydro-1 -H-indole-3-yl] ester-phenyl-amide
0.38 ml (3.1 mmol) chloroformic acid ethyl ester were added to 0.8 g (2.8 mmol) of the intermediate product 3b in 20 ml pyridine at 0° C, and then everything was stirred for 16 h at room temperature. Then the batch was poured on to icy water and extracted with ethyl acetate. The organic phase was washed with water, dried and concentrated in a vacuum. The residue obtained in this way was dissolved in a little ether and the product was precipitated by the careful addition of n-pentane. 1.1 g were obtained.
3d) 4-(4-Methyl-piperidine-1-yl)-piperazine-1-carboxylicacid-(5-chloro-2-oxo 3-phenyl-2,3-dihydro-1 H-indole-3-yl)-amide
1 g (2.4 mmol) of the intermediate product 3c and 1.8 g (9.8 mmol) 1(1-Methylpiperidine-4-yl)piperazine were boiled in 35 ml water-free tetrahydrofurane for 3 h with return flow. Then the solvent was removed in a vacuum. The residue obtained was distributed between water and ethyl acetate, the organic phase was separated, washed with water, dried and concentrated in a vacuum. The residue was treated with ether/pentane, after

58
which the product accumulated as a solid. 0.76 g were obtained.
3e) 4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-benzenesulfonyl)-5-chloro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-3-yl] amide dihydrochloride
0.052 mg (0.47 mmol) potassium-tert.-butanolate were added to 0.21 g (0.42 mmol) of the intermediate product 3d in 2 ml dimethylformamide at 0° C. Everything was stirred for 1 h at 0° C. After this, 0.11 g (0.47 mmol) 2.4-dimethoxybenzene sulfonic acid chloride was added. After this, the reaction mixture was stirred for 16 h more at room temperature. Then the mixture was poured into a 5% potassium carbonate solution, after which a precipitate slowly formed. This precipitate was isolated and chromatographically cleaned on silica gel (mobile phase: methylene chloride/methanol = 1/1). 0.1 g of the product was obtained. 1H-NMR (D6-DMSO): 5 = 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.1(4H), 3.1-3.3(1 H), 3.25-3.7(2H), 3.3-3.6(9H), 3.7(3H), 3.85(3H), 3.9-4.1 (1H), 6.7(2H), 6.95(1 H), 7.05(1 H), 7.3(1 H), 7.35(3H), 7.7(1 H), 7.9(2H) and 10.5(N+H, broad) ppm.
The following compounds were produced in a manner analogous to the methodical procedures described in examples 1, 2, 3 and 192:
Example 4
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-5-chloro-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride 1H-NMR (De-DMSO): 8 = 2.0(2H), 2.3(2H), 2.7(3H), 2.85-3.1(4H), 3.2-3.7(5H), 4.25(1 H), 7.15(2H), 7.35(3H), 7.55(1 H), 7.6(3H), 7.8(1 H), 7.9(1 H), 8.0(1 H) and 10.5(N+H, broad) ppm.
Example 5
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester

59
1H-NMR (De-DMSO): 8 = 1.05(1H), 1.40IH), 1.65(1H), 1.8(1H), 2.1(3H), 2.2-2.5(8H), 2.65(1 H), 3.0(1 H), 3.5(2H), 4.1(1 H), 7.1 (2H), 7.35(3H), 7.45(1 H), 7.55-7.7(3H), 7.8(1 H), 7.9(1 H) and 7.95(2H) ppm.
Example 6
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 2.05(2H), 2.7(3H), 2.9-3.1(4H), 3.1-3.3(2H), 3.3-
3.8(15H), 3.85(3H), 4.1-4.4(1 H), 6.75(3H), 6.95(2H), 7.05(1 H), 7.35(1 H),
7.65(1 H), 7.75(1 H), 7.85(1 H) and 10.5-11(N+H, broad) ppm.
Example 7
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.2-1.7(4H), 1.9-2.2(2H), 2.3(3H), 2.6-2.8(5H),
3.0(2H), 3.2-3.8(6H), 4.2(1 H), 7.1(3H), 7.3(4H), 7.6(2H), 7.7(2H)and 7.9(2H)
ppm.
Example 8
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 2.05(2H), 2.3(2H), 2.45(3H), 2.7(3H), 2.9-3.1 (4H),
3.1-3.25(1H), 3.25-3.7(1 OH), 3.75(3H), 3.85(3H), 4.1-4.4(1H), 6.6(1H),
6.7(2H), 6.85(1 H), 7.1(2H), 7.25(2H), 7.65(1H), 7.8(1H) and 10.5(N+H,
broad) ppm.
Example 9
4-(Piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimetnoxy-benzene-
sulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-3-yl]
ester

60
1H-NMR (De-DMSO): 6 = 1.4(2H), 1.7(2H), 2.25-2.4(3H), 2.55-2.7(2H), 3.05-3.2(4H), 3.25-3.4(2H), 3.45-3.6(8H), 3.65(3H), 3.85(3H), 6.55(1 H), 6.65(1 H), 6.7(1 H), 6.9(1 H), 6.95(1 H), 7.05(1 H), 7.35(1 H), 7.65(1 H), 7.7(1 H) and 7.85(1 H)ppm.
Example 10
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-fluoro-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (D6-DMSO): 8 = 1.2-1.5(4H), 1.65(2H), 1.85(2H), 2.1(3H), 2.15(1H),
2.3(2H), 2.75(2H), 3.2(2H), 3.5(2H), 3.55(3H), 3.6(3H), 3.85(3H), 6.65(1 H),
6.7(1 H), 6.95(1 H), 7.0(1 H), 7.1(1 H), 7.2(1 H), 7.4(1 H), 7.7(1 H), 7.75(1 H) and
7.85(1 H)ppm.
Example 11
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 2.0(2H), 2.3(2H), 2.4(3H), 2.7(3H), 2.8-3.1 (4H),
3.2-3.7(8H), 3.8(3H), 4.1-4.4(1H), 6.8(1H), 6.9(1H), 7.1(21-1), 7.2-7.4(31-1),
7.8-8.0(31-1), 8.1 (1H), 8.2(1 H) and 10.5(N+H, broad) ppm.
Example 12
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-bromo-2-
methyl-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methylphenyl)-2,3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 6 = 2.u(2hj, z.J(Zrt), 2.5(6H), 2.7(3H), 2.9-3.1(4H), 3.1-3.25(1H), 3.25-3.7(6H), 3.75(3H), 3.8(1H), 4.1-4.4(1H), 6.7(1H), 6.9(1H), 7.15(2H), 7.25(1H), 7.1-7.3(3H), 7.95(1H) and 10.5(N+H, broad) ppm.
Example 13
4-(1 -Benzyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-

61
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2)3-clihydro-1H-indole-3-yl] ester
1H-NMR (De-DMSO): 5 = 1.4(2H), 1.65(2H), 1.9(2H), 2.1-2.4(3H), 2.8(2H), 3.2(2H), 3.25-3.4(2H), 3.4(2H), 3.45-3.6(8H), 3.65(3H), 3.85(3H), 6.6(1 H), 6.65(2H), 6.9(1 H), 6.95(1 H), 7.05(1 H), 7.2-7.4(6H), 7.6(1 H), 7.65(1 H) and 7.85(1 H)ppm.
Example 14
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methyl-2-oxo-3-(2-methylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
1H-NMR (D20): 8 = 2.0(2H), 2.25(3H), 2.3(3H), 2.4(2H), 2.85(3H), 3.1(2H),
3.25(3H), 3.25-3.5(5H), 3.55(2H), 3.65(2H), 3.8(3H), 3.8-4.1(2H), 6.45(1 H), 6.65(1 H), 6.75(1 H), 7.05(1 H), 7.1(1 H), 7.2-7.4(4H), 7.6(1 H) and 7.95(1 H) ppm.
Example 15
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-cyano-2-oxo-3-(2-methylphenyl)-2f3-dihydro-1H-indole-
3-yl] ester dihydrochloride
1H-NMR (D20): 8 = 1.9(2H), 2.3(3H), 2.4(2H), 2.8(3H), 3.1(2H), 3.3(3H), 3.3-
3.5(4H), 3.5-3.8(6H), 3.8(3H), 3.8-4.1 (1H), 6.45(1 H), 6.65(1 H), 6.7(1 H),
7.1(1 H), 7.2-7.4(2H), 7.7(1 H) and 7.9-8.0(3H) ppm.
Example 16
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-Denzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1 H-indole-3-yl] amide dihydrochloride
1H-NMR (D20): 8 = 1.95(2H), 2.4(2H), 2.85(3H), 3.1(2H), 3.2-3.4(4H),
3.4(3H), 3.55(2H), 3.6(3H), 3.6-3.8(8H), 3.86(3H), 6.6(1 H), 6.7(1 H), 6.8-6.95(4H), 7.0(1 H), 7.35(1 H), 7.6(1 H) and 8.0(1 H) ppm.

62
Example 17
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methyl-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D20): 5 = 1.9(2H), 2.1 (3H), 2.4(2H), 2.8(3H), 3.1(2H), 3.25(2H),
3.35(2H), 3.4(3H), 3.5(2H), 3.7(3H), 3.75(1 H), 3.8(3H), 3.9-4.1 (2H),
6.65(1 H), 6.7(1 H), 6.95(1 H), 7.0(1 H), 7.1(1 H), 7.2(1 H), 7.4(1 H), 7.6(1 H),
7.8(1 H) and 8.0(1 H) ppm.
Example 18
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.1(3H), 1.2(3H), 2.05(2H), 2.3(2H), 2.7(3H), 2.8-
3.1(41-1), 3.2-4.0(151-1), 4.1-4.4(1H), 6.4(1H), 6.5(1H), 6.65(11-1), 6.85-7.0(1 H),
7.1 (1H), 7.35(1 H), 7.5(1 H), 7.6(2H), 7.85(1 H) and 10.5(N+H, broad) ppm.
Example 19
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-methoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.1 (3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.1 (4H), 3.1-3.7(8H), 3.7(1 H), 3.75(1 H), 3.8(3H), 4.1-4.4(1 H), 6.45(1 H), 6.9(1 H), 6.95-7.15(4H), 7.35(1 H), 7.5(1 H), 7.75(1 H), 7.8(2H) and 10.5(N+H, broad) ppm.
Exampie 20
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(3,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.2(3H), 1.25(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-
3.1(4H), 3.2-3.7(8H), 3.65(3H), 3.7(3H), 3.8(3H), 3.9(1H), 4.1-4.4(1H),

63
6.35(1 H), 6.9(1 H), 7.0(1 H), 7.1 (2H), 7.25(1 H), 7.35(1 H), 7.5(2H), 7.7(1 H) and 10.4(N+H, broad) ppm.
Example 21
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-isopropyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 6 = 1.1(6H), 1.2(6H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.1 (4H), 3.2-3.70(13H), 3.8(3H), 4.1-4.3(1 H), 6.45(1 H), 6.9(1 H), 7.0(1 H), 7.1(1 H), 7.3-7.5(3H), 7.5(1 H), 7.7-7.9(3H) and 10.6(N+H, broad) ppm.
Example 22
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1-(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.05(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.1(4H), 3.2-3.75(9H), 3.7(3H), 3.8(3H), 4.1-4.4(1H), 6.6(1H), 6.9(1H), 7.05(1 H), 7.15(1 H), 7.35(1 H), 7.45(1 H), 7.9(3H), 8.0(1 H), 8.15(1 H) and 10.5(N+H, broad) ppm.
Example 23
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-indole-3-yl]
ester dihydrochloride
1H-NMR (D20): 8 = 1.9(21-1), 2.4(2H), 2.8(3H), 3.1 (2H), 3.25(2H), 3.4(3H),
3.4-3.6(4H), 3.6(3H), 3.7(1 H), 3.85(3H), 3.9-4.1(2H), 6.65(1 H), 6.7(1 H),
6.9(1 H), 7.1(3H), 7.4(2H), 7.7(1 H), 7.8( iH) and 8.0(1 H) ppm.
Example 24
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acld-[1 -(2,4-dimethoxy-
benzenes"ulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride

64
1H-NMR (De-DMSO): 8 = 0.75(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.1(6H), 3.1-3.3(6H), 3.4-3.65(9H), 3.7(3H), 3.8(3H), 4.3(1H), 4.6(1H), 6.6(1 H), 6.65(2H), 7.35(1 H), 7.0(2H), 7.3(1 H), 7.7(2H), 7.8(1 H), 10.5-
11(N+H, broad) ppm.
Example 25
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 5 = 0.7(3H), 1.2(3H), 2.0(2H), 2.25(2H), 2.7(3H), 2.9-
3.2(6H), 3.2-3.6(6H), 3.65(3H), 4.3(1 H), 4.6(1 H), 6.6(1 H), 7.0(3H), 7.35(1 H),
7.75(1 H), 7.8-8.0(3H), 8.1(1 H), 8.2(1 H), 10.5-11(N+H, broad) ppm.
Example 26
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-benzene)-sulfonyl-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-
dihydro-1 H-indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 6 = 0.7(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.4(3H),
2.7(3H), 2.8-3.0(4H), 3.0-3.3(4H), 3.3-3.6(9H), 3.7(3H), 4.3(1 H), 4.5(1 H),
6.55(1 H), 6.9(1 H), 7.0(4H), 7.35(1 H), 7.7-7.8(3H), 10.5-11(N+H, broad) ppm.
Example 27
4-(1 -Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropylphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.1(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.4(3H),
2.7(3H), 2.9-4.1(4H), 3.1-3.3(2H)/ 3.3-3.9(1 *H), 4.1-4.3(1 H), 6.5(1H),
6.95(1 H), 7.0(1 H), 7.05(1 H), 7.3-7.45(3H), 7.5(1 H), 7.6(1 H), 7.7(1 H),
8.05(1H), 10.5-11(N+H, broad) ppm.
Example 28
4-(1 -Methyl-piperidine-4-yl)-piperazir>e-1 -carboxylic acid-[1 -(2-methyl-

65
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-isopropoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 5 = 0.7(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.6(3H), 2.7(3H), 2.9-3.1 (4H), 3.1-3.3(2H), 3.3-3.7(6H), 3.7(3H), 4.3(1 H), 4.6(1 H), 6.6(1H), 7.0(3H), 7.3(1H), 7.4(2H), 7.6(1H), 7.75(2H), 8.1(1H), 10.5-11(N+H,
broad) ppm.
Example 29
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2)3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.0(3H), 2.0(2H), 2.3(2H), 2.6(3H), 2.7(3H),
2.95(2H), 3.0-3.3(2H), 3.3-3.7(8H), 3.7(3H), 3.75(1 H), 3.9(1 H), 4.3(1 H),
6.7(1 H), 7.0(2H), 7.05(1 H), 7.35(1 H), 7.45(2H), 7.60(1 H), 7.65(1 H), 7.7(1 H),
8.1(11-1), 10.3-10.8(N+H, broad) ppm.
Example 30
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.05(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.8-3.25(6H),
3.3-3.7(9H), 3.7(3H), 3.75(1 H), 3.85(3H), 3.9(1 H), 4.3(1 H), 6.6-6.7(3H),
6.95(2H), 7.05(1 H), 7.35(1 H), 7.7(2H), 7.75(1 H) and 10.3-10.8(N+H, broad)
ppm.
Example 31
4-(1-Methyl-piperidine-4-yl)-piperazine- i-carboxyiic acid-[ i-(2-methyi- "
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D20): 8 = 1.9(2H), 2.4(2H), 2.6(3H), 2.85(3H)1 3.1(2H), 3.2-
3.7(15H), 3.9 7.65(1 H), 7.7(1 H), 7.8(1 H) and 8.2(1 H) ppm.

66
Example 32
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(3-cyano-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2l3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.1(3H), 2.1(2H), 2.3(2H), 2.7(3H), 2.8-3.1(4H),
3.1-3.3(2H), 3.3-3.65(6H), 3.65(3H), 3.8(1 H), 3.9(1 H), 4.3(1 H), 6.65(1 H),
6.95(2H), 7.05(1 H), 7.35(1 H), 7.75(1 H), 7.8(1 H), 7.85(1 H), 8.25(1 H),
8.3(1 H), 8.35(1 H) and 10.5-11(N+H, broad) ppm.
Example 33
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-ethyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 5 = 1.0(3H), 1.2(3H), 2.0(2H), 2.3(2H), 2.7(3H), 2.9-
3.1(41-1), 3.1-3.3(2H), 3.3-3.9(13H), 4.3(1H), 6.6(1H), 6.95(2H), 7.05(1H),
7.4(1 H), 7.5(2H), 7.7(1 H), 7.8(1 H), 7.9(2H) and 10.5-11(N+H, broad) ppm.
Example 34
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 0.7(3H), 1.9(2H), 2.05(2H), 2.3(2H), 2.6(3H),
2.7(3H), 2.7-3.7(15H), 3.7-3.9(2H), 4.3(1 H), 6.7(1 H), 6.95(2H), 7.05(1 H),
7.35(1 H), 7.4(2H), 7.6(1 H), 7.65(1 H), 7.75(1 H), 8.1(1 H), and 10.5-11(N+H,
broad) ppm.
Example 35
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methy1-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-propoxypheny1>2,3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 0.7(3H), 1.5(2H), 2.0(2H), 2.3(2H), 2.4(3H),

67
2.7(3H), 2.9-3.7(19H), 3.8(1 H), 4.3(1 H), 6.6(1 H), 6.7-7.1(5H), 7.35(1 H), 7.7(2H), 7.8(1 H) and 10.5-11(N+H, broad) ppm.
Example 36
4-(1 -Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1 -benzenesulfonyl-
5-methyl-2-oxo-3-phenyl-2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 5 = 2.0(2H), 2.2-2.4(2H), 2.3(3H), 2.7(1 H), 2.75(3H), 2.9-3.8(11H), 4.2(1 H), 7.1 (2H), 7.15(1 H), 7.3-7.5(4H), 7.6(2H), 7.75(2H) and 8.0(2H)ppm.
Example 37
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethylphenyl)-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
1H-NMR (D20): 5 = 1.1 (3H), 1.95(2H), 2.4(2H), 2.75(1 H), 2.8-3.0(4H),
3.1(2H), 3.15(3H), 3.2-3.5(4H), 3.5-3.65(4H), 3.65-3.75(8H), 3.8-4.1(3H),
6.35(1 H), 6.5(1H), 6.6(1H), 6.7(1H), 6.9(1H), 7.1(1H), 7.3(1H), 7.4(1H),
7.6(1 H) and 7.9(1 H) ppm.
Example 38
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2,5-dimethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D20): 5 = 1.9-2.1(2H), 2.4(2H), 2.9(3H), 3.1(2H), 3.2-3.6(11H),
3.65(3H), 3.7(3H), 3.8(3H), 3.9(3H), 3.9-4.2(3H), 6.65(1 H), 6.7(1 H),
6.75(1 H), 6.95(1 H), 7.0(2H), 7.3(1 H), 7.6(1 H) and 8.0(1 H) ppm.
Example 39
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-
benzenesulfony1)-5HTietho^^
indole-3-yl] ester dihydrochloride
1H-NMR (D20): 5 = 1.9-2.1(2H), 2.4-2.6
68
3.3(1 H), 3.3-3.6(7H), 3.6-3.75(4H), 3.8(3H), 3.9(3H), 3.9-4.2(2H), 6.9(1 H), 7.0(1H), 7.1(2H), 7.45(1H), 7.5(2H), 7.7(1H), 7.8(1H) and 8.3 ppm.
Example 40
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -
(benzenesulfonyl)-5-methoxy-2-oxo-3-(2,5-dimethoxyphenyl)-2)3-dihydro-
1 H-indole-3-yl] ester dihydrochloride
1H-NMR (D20): 8 = 1.95(2H), 2.4(2H), 2.85(3H), 3.1(2H), 3.2(3H), 3.2-
3.6(7H), 3.65(31-1), 3.7(2H), 3.75(3H), 3.8-4.2(2H), 6.75(1 H), 6.8(1 H),
6.95(2H), 7.3(1 H),7.6(2H), 7.75(2H) and 8.1(2H) ppm.
Example 41
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-cyano-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2I3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 5 = 1.3(3H), 1.5-1.7(2H), 1.7(2H), 1.9(2H), 2.2-2.35(4H),
2.4(2H), 2.5(2H), 2.8-3.05(4H), 3.55(2H), 3.8(1 H), 4.0(1 H), 6.8(1 H),
6.95(1 H), 7.0(1 H), 7.25-7.35(2H), 7.7(1 H), 7.75(2H), 7.9(1 H) and 8.2(1 H)
ppm.
Example 42
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.7(2H), 1.9(2H), 2.2-2.9(6H),
2.5(2H), 2.9(2H), 3.05(2H), 3.55(5H), 3.8(1 H), 4.05(1 H), 6.8(1 H), 6.9-
7.1(4H), V.25-7.3b(2N), 7.6(1 rij,"/.b5(iH), 7.y5(iH) and 8.15(1 H) ppm. "*
Example 43
4^14tethyH>iperidine^yl^^ methyl-1 -b©nzen©8U^yl)^ifo^ 1H-indole-3-y1] ester

69
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.7(2H), 1.9(2H), 2.2-2.6(11H), 2.9(2H), 3.1 (2H), 3.6(5H), 3.8(1 H), 4.05(1 H), 6.7(1 H), 6.8(1 H), 6.85(1 H), 6.95(2H), 7.3(2H), 7.65(1 H), 7.95(1 H) and 8.0(1 H) ppm.
Example 44
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.75(2H), 1.9(2H), 2.25(4H),
2.3(2H), 2.5(2H), 2.9(2H), 3.0(2H), 3.55(2H), 3.8(1 H), 4.0(1 H), 6.8(1 H),
6.9(1H), 7.0(1H), 7.3(2H), 7.5(2H), 7.6(1H), 7.7(1H), 7.9(1H) and 8.1(1H)
ppm.
Example 45
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.6(2H), 1.7(2H), 1.95(2H), 2.3(4H), 2.3(2H),
2.35(2H), 2.55(2H), 2.9(2H), 3.1(2H), 3.5-3.65(5H), 3.8(1H), 3.85(3H), 4.05(1 H), 6.4(1 H), 6.5(2H), 6.8(1 H), 6.9-7.0(2H), 7.3(2H), 7.65(1 H), 7.9(1 H) and 8.05(1 H) ppm.
Example 46
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-methoxyphenyl)-2l3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 8 = 2.05(2H), 2.3(2H), 2.65-2.8(3H), 2.9-3.7(18H),
3.9(3H), 4.3(1 H), 6.7(2H), 7.0(1 H), 7.1(1 ri), 7.1 (iH), 7.4(1 H), 7.4o(iH),
7.8(1 H), 7.9(1 H), 10.6(N+-H) and 11.7(N+-H) ppm.
Example 47
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 - methyl-1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-

70
1 H-indole-3-yl] amide
1H-NMR (CDCt3): 5 = 1.5(3H), 1.6(2H), 1.75(2H), 1.95(2H), 2.25(4H), 2.35(3H), 2.45(4H), 2.9(2H), 3.2(4H), 3.55(3H), 4.1-4.3(2H), 6.7(1 H), 6.8-7.0(5H), 7.25(2H), 7.3(1 H), 7.85(1 H) and 8.0(1 H) ppm.
Example 48
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-(2,4,6-trimethyl-1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2)3-dihydra-1H-indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.15(3H), 1.6(2H), 1.7(2H), 1.9(2H), 2.2-2.3(7H), 2.4(2H), 2.5(2H), 2.7(6H), 2.9(2H), 3.1 (1H), 3.35(1 H), 3.55(1 H), 3.6(1 H), 3.85(1 H), 4.05(1 H), 6.8(1 H), 6.9(2H), 7.0(2H), 7.2-7.3(2H), 7.65(1 H) and 7.95(1 H) ppm.
Example 49
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dichloro-1 -
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.2(3H), 1.6(2H), 1.75(2H), 1.9(2H), 2.2-2.4(4H), 2.4-
2.6(3H), 2.9(2H), 3.1 (2H), 3.6(2H), 3.75(3H), 3.8(1 H), 4.05(1 H), 6.55(1 H),
6.75(1 H), 6.85(1 H), 7.0(1 H), 7.3(1 H), 7.35(1 H), 7.45(1 H), 7.65(1 H), 7.9(1 H)
and 8.3(1 H) ppm.
Example 50
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2-
trifluoromethoxy-1-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-
2,3-dihydro-i H-indole-3-yi] ester '
1H-NMR (CDCI3): 8 = 1.15(3H), 1.4-1.8(4H), 1.9(2H), 2.2-2.7(8H), 2.8-
3.0(3H), 3.05(1 H), 3.55(1 H), 3.7(3H), 3.8(1 H), 4.05(1 H), 6.55(1 H), 6.75(1 H),
6.85(1 H), 6.95(1 H), 7.2-7.45(3H), 7.55(1 H), 7.65(1 H), 7.9(1 H) and 8.3(1 H)
ppm.

71
Example 51
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.4-1.8(4H), 1.9(2H), 2.2-2.6(8H), 2.9(2H), 3.05(2H), 3.5-3.7(4H), 3.75(3H), 3.8(1 H), 4.05(1 H), 6.55(1 H), 6.75(1 H), 6.8-7.1 (4H), 7.25(1 H), 7.5(1 H), 7.7(1 H), 7.9(1 H) and 8.15(1 H) ppm.
Example 52
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[1-benzenesulfonyl-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.25(3H), 1.5-1.8(4H), 1.9(2H), 2.2-2.4(6H), 2.5(2H), 2.9(2H), 3.0(2H), 3.55(2H), 3.7(3H), 3.75(1 H), 4.0(1 H), 6.5(1 H), 6.75(1 H), 6.8(1 H), 7.0(1 H), 7.25(1 H), 7.45(1 H), 7.6(1 H), 7.7(1 H), 7.85(1 H) and 8.15(11-1) ppm.
Example 53
1-(2.4-Dimethoxy-1-benzenesulfonyl)-5-methoxy-3-(2-methoxyphenyl)-3{2[4-
methyl-piperidine-1 -yl)-piperazine-1 -yl]-2-oxo-ethoxy}-1,3-dihydroindolone
dihydrochloride
1H-NMR (De-DMSO): 8 = 2.1(2H), 2.3(2H), 2.7(3H), 2.8-3.3(6H), 3.3-3.7(8H),
3.7-4.0(12H), 4.25(1 H), 6.5(1 H), 6.8(2H), 6.95(1 H), 7.1-7.15(2H), 7.35(1 H),
7.7(1H), 7.75(1H), 7.95(1H), 10.6(N+-H) and 11.8(N+-H) ppm.
Example 54
1-(2,4-Dimethoxy-1-benzenesulfonyl)-5-methoxy-3-(2-methoxyphenyl)-3{2[4-metnyl-piperazine-T-yl)-piperidine-i-yl]-2-oxo-ethoxy}-1,3-dihydTX>indo!one 1H-NMR (D6-DMSO): 8 = 1.5(2H), 2.1(2H), 2.8(3H), 2.9(1 H), 3.25-3.8(22H), 3.9(3H), 4.3(1 H), 6.5(1 H), 6.75(2H), 6.95(1 H), 7.05(1 H), 7.15(1 H), 7.35(1 H), 7.75(1H), 7.8(1H>and 7.95(1H)Upm.
Example 55

72
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1-benzenesulfonyl)-5-methoxy-2-oxo-3-(2-methoxyphenyl)-2)3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.4(1H), 1.6(1H), 2.1(2H), 2.7(1H), 2.8(3H),
3.0(1 H), 3.25-3.8(19H), 3.9(3H), 4.3(1 H), 6.6(1 H), 6.65(1 H), 6.9-7.0(2H),
7.05(1 H), 7.35(1 H), 7.65(1 H), 7.7(1 H) and 7.9(1 H) ppm.
Example 56
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methyl-1 -
benzenesulfonyl)-5-methoxy-2-oxo-3-[2-(2-methoxyethyl)phenyl]-2,3-
dihydro-1 H-indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 2.15(2H), 2.3(2H), 2.4(3H), 2.7(3H), 2.9-3.2(5H),
3.25-3.7(1 OH), 3.8(3H), 3.85(1 H), 4.25(1 H), 6.55(1 H), 7.0(1 H), 7.1(2H),
7.30-7.5(4H), 7.6(1 H), 7.7(1 H) and 8.05(1 H) ppm.
Example 57
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-4-
methyl-1-benzenesulfonyl)-5-methoxy-2-oxo-3-[2-(2-methoxyethyl)phenyl]-
2,3-dihydro-1 H-indole-3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 8 = 2.1(2H), 2.3(2H), 2.35(3H), 2.7(3H), 2.9-3.2(5H),
3.25-3.7(16H), 3.8(3H), 3.85(1 H), 4.25(1 H), 6.5(1 H), 6.8-7.0(3H), 7.1 (2H),
7.35(1 H), 7.4(1 H), 7.65(1 H), 7.75(1 H), 10.6(N+-H) and 11.8(N+-H) ppm.
Example 58
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1-benzenesulfonyl)-5-methoxy-2-oxo-3-[2-(2-methoxyethyl)phenyl]-2,3-
dihydro-i H:inaoie-3-ylj ester aihydrbchibride -
1H-NMR (D6-DMSO): 8 = 2.1 (2H), 2.3(2H), 2.7(3H), 2.8-3.2(5H), 3.25-
3.7(16H), 3.75(3H), 3.8-3.9(4H), 4.25(1 H), 6.45(1 H), 6.55(1 H), 6.65(1 H),
6.9(1H), 7.1(2H), 7.35(1H), 7.4(1H), 7.65(1H), 7.75(1H), 10.6(N+-H) and
11.8(N+-H)ppm.

73
Example 59
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.3(4H), 2.35-2.6(4H), 2.9(2H), 3.25(2H), 3.4(6H), 3.55(2H), 3.85(3H), 4.7(1 H), 5.0(1 H), 6.35(1 H), 6.55(2H), 7.05-7.15(1 H), 7.35(1 H), 7.4(1 H), 7.65(1 H), 7.9(1 H) and 8.0(1 H) ppm.
Example 60
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 8 = 1.5-1.7(5H), 1.75(2H), 1.9(2H), 2.15-2.35(4H),
2.45(4H), 2.9(2H), 3.25(4H), 3.55(3H), 3.75(3H), 3.85(3H), 4.2(2H), 6.4(1 H),
6.55(1 H), 6.75-6.95(5H), 7.05(1 H), 7.2(1 H), 7.8(1 H) and 8.1(1 H) ppm.
Example 61
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-methoxy-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
1H-NMR (De-DMSO): 8 = 1.25(3H), 2.0(2H), 2.3(2H), 2.75(3H), 2.75-3.0(4H),
3.15(2H), 3.3-3.6(4H), 3.65(3H), 3.75-4.1(4H), 6.85(2H), 6.85-7.0(2H), 7.25-
7.45(2H), 7.6(3H), 7.75(1 H), 7.9(1 H), 8.05(1 H), 10.4(N+-H) and 11.1(N+-H)
ppm.
Example 62
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-cyano-2-oxo-3-(2-ethoxyphenyl)-2I3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.2(3H), 1.4-2.1(6H), 2.3-2J(8H), 2.9(2H), 3.15(2H)1 3.6(2H), 3.75(1H), 4.0(1H), 6.8(1H), 7.0(1H), 7.25(1H), 7.3(1H), 7.5(2H), 7.6-7.75(3H) and 8.1 (3H) ppm.

74
Example 63
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
1 -benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2)3-clihyclro-1 H-
indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.5-1.9(6H), 2.1(1 H), 2.25-2.5(4H), 2.55(2H),
2.95-3.2(4H), 3.55(3H), 3.6(2H), 3.8(1 H), 3.85(3H), 4.05(1 H), 6.4(1 H),
6.55(1 H), 6.8(1 H), 7.0(1 H), 7.25(2H), 7.65(2H), 8.05(1 H) and 8.15(1 H) ppm.
Example 64
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dichloro-1 -
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
Example 65
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-1 -
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.5-1.9(6H), 2.1(1H), 2.25-2.5(4H), 2.55(2H), 2.95-3.2(4H), 3.55(3H), 3.6(2H), 3.8(1 H), 3.85(3H), 4.05(1 H), 6.4(1 H), 6.55(1 H), 6.8(1 H), 7.0(1 H), 7.25(2H), 7.65(2H), 8.05(1 H) and 8.15(1 H) ppm.
Example 66
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2>3-dihydro-1H-indole-
3-yl] amide dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.2(3H), 2.1(2H), 2.3(2H), 2.7(3H), 2.9(4H),
3.2(2H), 3.3-3.7(8H), 3.8-4.0(5H), 4.05(2H), 6.65(2H), 6.9(1 H), 7.0(1 H),
7.2(1 H), 7.25-7.4(3H), 7.7(1 H), 7.9(2H), 10.5(N+-H) and 11.3(N+-H) ppm.
Example 67
4-(1 -Methyl-piperidine-4-y1)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-

75
5-chloro-2-oxo-3-(2-ethoxyphenyl)-2I3-clihyclro-1 H-indole-3-yl] amide
dihydrochloride
1H-NMR (De-DMSO): 8 = 1.1(3H), 2.1(2H), 2.3(2H), 2.7(3H), 2.8-3.0(4H),
3.2(2H), 3.3-3.7(4H), 3.8-4.0(4H), 6.95(2H), 7.2(1 H), 7.35(2H), 7.55(1 H),
7.65(2H), 7.7-7.85(2H), 7.95(1 H), 8.05(1 H), 10.5(N+-H) and 11.3(N+-H) ppm.
Example 68
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -caFboxylic acid-[1 -(2,4,6-trimethyl-
1-benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
1H-NMR (De-DMSO): 6 = 1.2(3H), 2.05(2H), 2.3(6H), 2.6(3H), 2.85-3.05(4H),
3.2(2H), 3.4-3.7(4H), 3.95(2H), 4.05(2H), 6.85(2H), 7.0(1 H), 7.1 (3H),
7.3(1H), 7.35(1H), 7.45(1H), 7.75(1H), 7.95(1H), 10.5(N+-H) and 11.2(N+-H)
ppm.
Example 69
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-isopropyl-1 -
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] amide
Example 70
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(4-cyano-1-
benzenesulfonyl)-5-chloro-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.5(3H), 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.3(4H),
2.45(4H), 2.9(2H), 3.05-3.25(4H), 4.1 (1H), 4.2(1 H), 6.5(1 H), 6.9(2H),
7.1(1 H), 7.15(1 H), 7.25-7.35(2H), 7.75(2H), 7.85(1 ri) and 8.2(1 H) ppm.
Example 71
4-(1 -Methyl-piperldine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-ethoxy-phenyl)-1 -(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl] amide

76
1H-NMR (CDCI3): 5 = 1.5(3H), 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.35(4H), 2.45(4H), 2.9(2H), 3.25(4H), 3.6(3H), 4.1-4.25(2H), 6.75-6.85(2H), 6.9(3H), 7.1(1 H), 7.25(2H), 7.35(1 H), 7.55(2H), 7.9(1 H) and 8.15(1 H) ppm.
Example 72
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.65(2H), 1.75(2H), 2.05(2H), 2.2-2.7(8H),
2.95(2H), 3.1(2H), 3.6(5H), 3.75-3.9(4H), 4.05(1H), 6.4(1H), 6.55(1H),
6.7(1 H), 6.8(1 H), 6.9-7.1 (2H), 7.3(1 H), 7.65(1 H), 7.95(1 H) and 8.1(1 H) ppm.
Example 73
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-3-yl] ester 1H-NMR (CDCI3): 6 = 1.25(3H), 1.65(2H), 1.75(2H), 2.0(2H), 2.2-2.7(8H), 2.85-3.15(4H), 3.6(2H), 3.8(1 H), 4.0(1 H), 6.7(1 H), 6.8(1 H), 7.0(2H), 7.3(1 H), 7.5(2H), 7.6(1 H), 7.7(1 H), 7.9(1 H) and 8.15(2H) ppm.
Example 74
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.4-1.9(6H), 2.2(2H), 2.25-2.7(6H), 2.9-
3.2(4H), 3.6(2H), 3.8(1 H), 3.85(3H), 4.0(1 H), 6.8(1 H), 6.95(2H), 7.05(1 H),
7.3(1 H), 7.35(1 H), 7.65(1 H), 7.7(1 H) and 8.05(3H) ppm.
Example 75
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-isopropoxy-
phenyl)-5-methoxy-1 -(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.35(3H), 1.5-1.7(4H), 1.95(2H), 2.2-2.4(6H),

77
2.5(21-1), 2.9(2H), 3.0(2H), 3.6(2H), 3.7(3H), 3.8(3H), 4.5(1 H), 6.5(1 H), 6.8(1 H), 6.85(1 H), 6.9-7.0(3H), 7.25(1 H), 7.7(1 H), 7.85(2H) and 8.05(2H) ppm.
Example 76
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1 -(4-
methoxy-benzenesulfonyl)-2-oxo-3-(2-propoxy-phenyl)-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 5 = 0.8(3H), 1.5-1.85(6H), 1.9(2H), 2.2-2.3(4H), 2.35(2H),
2.5(2H), 2.9(2H), 3.05(2H), 3.6(2H), 3.65-3.75(4H), 3.85(3H), 3.9(1 H),
6.55(1 H), 6.8(2H), 6.9(2H), 7.0(1 H), 7.25(1 H), 7.7(1 H), 7.85(1 H) and
8.15(2H)ppm.
Example 77
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR(CDCI3): 8 = 1.5-1.75(5H), 1.75(2H), 1.9(2H), 2.2-2.35(4H), 2.4(4H),
2.9(2H), 3.15-3.3(4H), 3.85(3H), 4.15(1 H), 4.2(1 H), 6.65(1 H), 6.85-7.05(5H),
7.2-7.3(3H), 7.8(1 H) and 8.15(2H) ppm.
Example 78
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-{5-methoxy-1 -(2-
methoxy-benzenesulfonyl)-3-[2-(2-methoxy-ethyl)-phenyl]-2-oxo-2,3-dihydro-
1 H-indole-3-yl} amide dihydrochloride
1H-NMR (De-DMSO): 8 = 2.05(2H), 2.3(2H), 2.7(3H), 2.85-3.2(5H), 3.25-
3.7(16H), 3.75(3H), 3.85(1 H), 4.25(iri;, o.d(iri), 6.9(in), 7.25(1 H), 7.4(1H),
7.75(2H), 7.9(1 H), 10.5(N+-H) and 11.7(N+-H) ppm.
Example 79
4-(1 -Methyl-piperldine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1 -(2-
methoxy-benzenesulfonyl)-2-oxo-3-(2-propoxy-phenyl)-2f3-dihydro-1H-

78
indole-3-yl] ester
1H-NMR (CDCb): 5 = 0.8(3H), 1.4-1.85(6H), 1.9(2H), 2.2-2.4(6H), 2.5(2H), 2.9(2H), 3.1 (2H), 3.55(2H), 3.6(3H), 3.7(4H), 3.95(1 H), 6.55(1 H), 6.65-7.05(5H), 7.25(1 H), 7.5(1 H), 7.65(1 H), 7.9(1 H) and 8.1 (1H) ppm.
Example 80
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[3-(2-isopropoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 5 = 0.9(3H), 1.4(3H), 1.5-1.8(4H), 1.95(2H), 2.2-2.45(6H),
2.5(2H), 2.9(2H), 3.05(2H), 3.45-3.65(5H), 3.7(3H), 4.5(1 H), 6.5(1 H),
6.8(1 H), 6.85-6.95(3H), 7.0(1 H), 7.25(1 H), 7.5(1 H), 7.7(1 H), 7.9(1 H) and
8.15(1 H) ppm.
Example 81
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-methoxy-1 -(4-
methoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.5-1.9(4H), 2.0(2H), 2.2-2.6(8H), 2.95(2H), 3.2(2H),
3.3-3.7(9H), 3.75(3H), 3.85(3H), 6.6(1 H), 6.7(1 H), 6.85-7.05(4H), 7.25(1 H),
7.35(1 H), 7.85(1 H) and 8.20(1 H) ppm.
Example 82
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-benzenesulfonyl-5-chloro-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.4-1.8(6H), 1.9(2H), 2.2-2.3(4H), 2.35(1 H), 2.4(2H), 2.55(1 H), 2.9(2H), 3.15(2H), 3.4(3H), 3.55(2H), 4.75(1H), 5.0(1H), 6.55(ih), 7.05-7.15(2H), 7.3-7.55(4H), 7.6-7.7(2H), 7.95(1 H) and 8.05(1 H) ppm.
Example 83
4-(4-Methyl-piperazine-1-yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1 -(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-

79
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.1(1H), 1.25(3H), 1.35-1.9(5H), 2.25-2.7(11H),
2.9(1 H), 3.6(3H), 3.65(1 H), 3.7(3H), 3.75(1 H), 4.05(1 H), 4.25(1 H), 6.55(1 H), 6.75(1 H), 6.8-7.1 (4H), 7.3(1 H), 7.5(1 H), 7.7(1 H), 7.9(1 H) and 8.15(1 H) ppm.
Example 84
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.2(1H), 1.25(3H), 1.35-1.9(5H), 2.25-2.7(11H),
2.9(1 H), 3.55(3H), 3.65-3.7(4H), 3.8(1 H), 3.85(3H), 4.05(1 H), 4.25(1 H),
6.4(1 H), 6.55(2H), 6.75(1 H), 6.85(1 H), 6.95(1 H), 7.25(1 H), 7.7(1 H), 7.85(1 H)
and 8.05(1 H) ppm.
Example 85
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.35-1.9(6H), 2.25-2.7(11H), 2.9(1 H),
3.6(1 H), 3.7(3H), 3.8(1 H), 3.85(3H), 4.0(1 H), 4.25(1 H), 6.5(1 H), 6.75(1 H),
6.8(1 H), 6.95(2H), 7.0(1 H), 7.25(1 H), 7.7(1 H), 7.85(1 H) and 8.1 (2H) ppm.
Example 86
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[3-(2-isopropoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 0.85(3ri), 1.1(1H), 1.25-1.9(11H), 2.2-2.7(11H),
2.85(1 H), 3.5-3.65(4H), 3.7(3H), 4.2(1 H), 4.5(1 H), 6.5(1 H), 6.75(1 H), 6.8-
7.1(5H), 7.25(1H), 7.7(1H), 7.9(1H) and 8.15(2H) ppm.
Example 87
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -(2,4-dimethoxy-

80
benzenesulfonyl)-3-(2-isopropoxy-phenyl)-5-methoxy-2-oxo-2)3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCb): 6 = 0.85(3H), 1.1-1.9(9H), 2.2-2.75(11H), 2.9(1 H), 3.6(4H), 3.65-3.75(4H), 3.8(3H), 4.25(1 H), 4.5(1 H), 6.4(1 H), 6.5(2H), 6.75(1 H), 6.85(1 H), 6.9(1 H), 7.25(1 H), 7.7(1 H), 7.9(1 H) and 8.1(1 H) ppm.
Example 88
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.35-2.0(6H), 2.2-2J5(10H), 2.9(1H),
3.6(1 H), 3.75-3.9(4H), 4.0(1 H), 4.25(1 H), 6.8(1 H), 6.95(3H), 7.0(1 H),
7.3(2H), 7.7(1 H), 7.85(1 H) and 8.05(1 H) ppm.
Example 89
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acld-[3-(2-isopropoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2l3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 0.85(1 H), 1.1-1.9(9H), 2.2-2.7(11H), 2.9(1 H), 3.6(1 H),
3.7(3H), 3.85(3H), 4.25(1 H), 4.5(1 H), 6.5(1 H), 6.8(1 H), 6.85(1 H), 6.85-
7.0(3H), 7.3(1 H), 7.7(1 H), 7.85(1 H) and 8.05(2H) ppm.
Example 90
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
;H-NMR(CDCl3): 6 = 1.1(11-1), 1.25(3N), 1.35-1.9(5h), 2.2-2.7(i 1H), 2.9(tH),
3.5-3.7(4H), 3.8(1 H), 4.05(1 H), 4.25(1 H), 6.8(1 H), 6.9-7.1 (4H), 7.3(2H),
7.5(1 H), 7.65(1 H), 7.95(1 H) and 8.15(1 H) ppm.
Example 91
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-1 -(2,4-

81
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihyclro-1H-indole-3-yl] ester
1H-NMR (CDCb): 8 = 0.85(3H), 1.0-1.9(6H), 2.25(3H), 2.25-2.7(8H), 2.9(1 H), 3.55(3H), 3.65(1 H), 3.75-3.85(4H), 4.05(1 H), 4.2(1 H), 6.4(1 H), 6.5(1 H), 6.75(1 H), 6.9-7.1 (2H), 7.3(2H), 7.7(1 H), 7.9(1 H) and 8.05(1 H) ppm.
Example 92
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-
benzenesulfonyl)-3-(2-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3-dihydro-
1 H-indole-3-yl] ester
Example 93
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-fluoro-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.5-1.8(4H), 1.9(21-1), 2.2-2.6(8H), 2.9(2H),
3.1 (2H), 3.5-3.7(5H), 3.8(3H), 4.05(3H), 6.7(1 H), 6.8(1 H), 6.9-7.1 (4H),
7.25(1 H), 7.5(1 H), 7.65(1 H), 7.95(1 H) and 8.150(1 H) ppm.
Example 94
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-fluoro-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.0(3H), 2.05(2H), 2.3(2H), 2.7(3H), 2.8-3.9(17H),
4.3(1 H), 6.95-7.05(2H), 7.1 (2H), 7.25(1 H), 7.35(1 H), 7.75(2H), 7.95(2H),
10.5(NH+) and 11.6(NH+) ppm.
Example 95
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-cyano-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-lndole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.3(3H), 1.5-1.8(4H), 1.9(2H), 2.2-2.6(8H), 2.8-

82
3.05(4H), 3.55(21-1), 3.8(1 H), 4.05(3H), 6.7(1 H), 6.8(1 H), 7.05(2H), 7.3(1 H), 7.7(1 H), 7.8(2H), 7.9(1 H) and 8.2(1 H) ppm.
Example 96
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 5 = 2.1 (2H), 2.3(2H), 2.7(3H), 2.9(2H), 3.0-3.8(13H),
3.85(3H), 4.25(1 H), 4.7(1 H), 4.8(1 H), 6.5(1 H), 7.1 (2H), 7.2(1 H), 7.4(1 H),
7.5(1 H), 7.6(2H), 7.8-7.9(3H), 10.5(NH+) and 11.7(NH+) ppm.
Example 97
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-chloro-1 -(2-
methoxy-benzenesulfonyl)-3-(2-methoxymethyl-phenyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.6(21-1), 1.7(2H), 1.9(2H), 2.5(4H), 2.4-2.6(4H),
2.9(2H), 3.25(2H), 3.4(3H), 3.5(3H), 3.6(2H), 4.3(1 H), 5.0(1 H), 6.55(1 H),
6.85(1 H), 7.0-7.2(3H), 7.35(1 H), 7.45(1 H), 7.55(1 H), 7.65(1 H), 7.95(1 H) and
8.1(1H)ppm.
Example 98
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 8 = 1.4-1.65(5H), 1.75(2H), 1.9(2H), 2.15-2.35(4H),
2.45(4H), 2.9(2H), 3.25(4H), 3.55(3H), 3.75(3H), 4.15(2H), 6.75-6.85(3H),
6.9(3H), 7.0(1 H), 7.05(1 H), 7.2(1 H), 7.5(1 H), 7.8(1 H) and 8.1-5(1!-!) ppm.
Example 99
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1 -(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl] amide

83
1H-NMR (CDCI3): 8 = 1.4-1.6(5H), 1.75(2H), 1.9(2H), 2.15-2.35(4H), 2.35-2.5(4H), 2.9(2H), 3.15-3.35(4H), 3.7(3H), 3.85(3H), 4.1-4.3(2H), 6.7-6.9(8H), 7.25(1 H), 7.75(1 H) and 8.05(1 H) ppm.
Example 100
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-methoxy-phenyl)-2-oxo-6-trifluoromethyl-2,3-dihydro-
1 H-indole-3-yl] ester
Example 101
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.15(3H), 1.3-1.5(2H), 1.9-2.1(2H), 2.5-2.7(2H),
2.8(3H), 3.2-3.8(9H), 3.8-4.1 (7H), 6.95(2H), 7.15(2H), 7.25(1 H), 7.3(2H),
7.4(1 H), 7.7(1 H), 7.75(1 H) and 7.9(2H) ppm.
Example 102
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
1H-NMR (De-DMSO): 8 = 1.2(3H), 1.3-1.5(2H), 1.9-2.1 (2H), 2.65(2H),
2.8(3H), 3.2-3.8(12H), 3.85(3H), 3.95(2H), 4.05(2H), 6.6-6.7(2H), 6.85(1 H),
7.0(1 H), 7.1(1 H), 7.25-7.4(3H), 7.7(2H) and 7.9(1 H) ppm.
Example 103
4^4-iviethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-chloro-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 5 = 1.2-1.4(2H), 1.55(3H), 1.75(2^, 2.2-2.8(14H),
3.55(3H), 3.75(2H), 4.2(2H), 6.8(1 H), 6.85(1 H), 6.9-7.0(3H), 7.05(1 H), 7.25(2H), 7.3(1H), 7.55(1H), 7.9(1H) and 8.15(1H) ppm.

84
Example 104
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-phenyl)-2-oxo-1 -(toluene-2-sulfonyl)-2,3-dihyclro-1 H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.2(31-1), 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.45(6H), 2.55(2H), 2.65(3H), 2.9(2H), 3.05(1 H), 3.15(1 H), 3.55(2H), 3.85(1 H), 4.05(1 H), 6.8(1 H), 7.0(1 H), 7.3(1 H), 7.35(1 H), 7.45(1 H), 7.65(1 H), 8.05(1 H) and 8.25(1 H) ppm.
Example 105
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-phenyl)-2-oxo-1 -(toluene-4-sulfonyl)-2,3-dihydro-1 H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.2(3H), 1.6(2H), 1.75(2H), 2.05(2H), 2.2-2.45(9H), 2.5(1 H), 2.6(1 H), 2.9-3.2(4H), 3.6(2H), 3.8(1 H), 4.0(1 H), 6.8(1 H), 7.05(1 H), 7.2-7.4(4H), 7.65(1 H), 7.7(1 H), 8.0(2H) and 8.05(1 H) ppm.
Example 106
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-chloro-
benzenesulfonyl)-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.2(3H), 1.6(2H), 1.75(2H), 1.9(2H), 2.2-2.3(4H), 2.35(2H), 2.5(1 H), 2.6(1 H), 2.8(2H), 3.0(1 H), 3.15(1 H), 3.6(2H), 3.8(1 H), 4.05(1 H), 6.8(1 H), 7.0(1 H), 7.25-7.35(2H), 7.4(1 H), 7.5(2H), 7.65(2H), 8.15(1 H) and 8.4(1 H) ppm.
Example 107
4-(1-Methyi-piperidine-4-yl)-piperazirfe-1 -carboxylic acid-[5-cyano-1-(2,5-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.250H), 1.6(2H), 1.75(2H), 1.9(2H), 2.2-2.3(4H),
2.35(2H), 2.55(2H), 2.9(2H)f 3.1(2H), 3.5-3.7(5H), 3.8(4H), 4.05(1 H),
6.8(1 H), 6.85(1 H), 7.0(1 H). 7.1(1 H), 7.25-7.35(2H), 7.6-7.75(3H) and

85
8.15(1H)ppm.
Example 108
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[5-cyano-1-(2-
cyano-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.6(2H), 1.7(2H), 1.95(2H), 2.2-2.4(6H), 2.45(1 H), 2.6(1 H), 2.7-3.1 (4H), 3.5(1 H), 3.6(1 H), 3.8(1 H), 4.05(1 H), 6.8(1 H), 7.05(1 H), 7.2(1 H), 7.35(1 H), 7.6-7.8(4H), 7.85(1 H), 8.3(1 H) and 8.4(1 H) ppm.
Example 109
4-(1-Methyl-piperidine-4-yl)-piperazine-1-carboxylicacid-[5-cyano-1-(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.6(2H), 1.7(2H), 1.95(2H), 2.2-2.45(6H),
2.55(2H), 2.8-3.2(4H), 3.6(2H), 3.8(1H), 4.05(1 H), 6.8(1H), 6.95-7.1(2H),
7.25(1 H), 7.3(1 H), 7.7(2H), 8.1 (1H) and 8.15(1 H) ppm.
Example 110
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-lndole-3-
yl] ester
1H-NMR (CDCI3): 8 = 1.25(31-1), 1.55(2H), 1.75(2H), 1.95(2H), 2.2-2.3(4H),
2.35(2H), 2.55(2H), 2.9(2H), 3.0(2H), 3.6(2H), 3.8(1 H), 4.0(1 H), 6.8(1 H),
7.05(1 H), 7.15(2H), 7.25(1 H), 7.3(1 H), 7.65(1 H), 7.7(1 H), 8.05(1 H) and
8.15(1 h) ppm.
Example 111
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-phenyO-1 -(4-isopropyl-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl] ester

86
1H-NMR(CDCI3): 8 = 1.2-1.3(9H), 1.55(21-1), 1.75(2H), 1.95(2H), 2.2-2.4(6H), 2.45(1 H), 2.6(1 H), 2.8-3.1(5H), 3.6(2H), 3.75(1 H), 4.0(1 H), 6.8(1 H), 7.05(1 H), 7.25(1 H), 7.3-7.4(1 H), 7.65(1 H), 7.7(1 H), 8.0(1 H) and 8.1(1 H) ppm.
Example 112
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-fluoro-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.4(6H),
2.5(1 H), 2.6(1 H), 2.85-3.0(3H), 3.1(1 H), 3.6(2H), 3.8(1 H), 4.05(1 H), 6.8(1 H),
7.05(1 H), 7.15(1 H), 7.2-7.4(3H), 7.6(1 H), 7.7(2H) and 8.15(1 H) ppm.
Example 113
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(5-chloro-2-
methoxy-benzenesulfonyl)-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.6(2H), 1.75(2H), 1.95(2H), 2.2-2.45(5H),
2.55(2H), 2.9(2H), 3.05(2H), 3.5-3.7(5H), 3.8(1 H), 4.05(1 H), 6.8(1 H),
6.85(1 H), 7.0(1 H), 7.2-7.4(2H), 7.45(1 H), 7.7(2H) and 8.1(2H) ppm.
Example 114
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-5-methyl-benzenesulfonyl)-2-oxo-2,3-dihydro-
1 H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.7(2H), 1.9(2H), 2.2-2.3(4H), 2.3-
2.45(5H), 2.55(2H), 2.9(2H), 3.1(2H), 3.5-3.7(5h)," 3.8(1 H>, 4.0SCtK),
6.8(2H), 7.0(1 H), 7.2-7.4(3H), 7.65(2H), 7.9(1 H) and 8.1 (1H) ppm.
Example 115
4^1-Methyl-plperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-4-methyl-benzenesulfonyl)-2-oxo-2,3-dihydro-

87
1 H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.7(2H), 1.9(2H), 2.2-2.3(4H), 2.3-
2.45(5H), 2.55(2H), 2.9(2H), 3.1 (2H), 3.5-3.7(5H), 3.8(1 H), 4.05(1 H),
6.7(1 H), 6.8(1 H), 6.85(1 H), 7.0(1 H), 7.3(2H), 7.65(2H), 8.0(1 H) and 8.15(1 H)
ppm.
Example 116
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-
5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
1H-NMR (D20): 8 = 0.95(3H), 1.85(2H), 2.3(2H), 2.8(3H), 3.05(2H), 3.1-
3.55(9H), 3.6(2H), 3.7(1 H), 3.8(1 H), 6.85(1 H), 6.95(1 H), 7.25(1 H), 7.45(1 H),
7.5(3H), 7.6-7.7(2H) and 7.8-8.0(3H) ppm.
Example 117
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.4-1.8(7H)f 1.95(2H), 2.25(4H), 2.45(4H), 2.9(2H),
3.1-3.3(4H), 3.85(3H), 4.1(1H), 4.2(1H), 6.5(1H), 6.85-7.0(4H), 7.1(1H),
7.3(1 H), 7.5(1 H), 7.6(1 H) and 7.95-8.1 (3H) ppm.
Example 118
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide dihydrochloride
1H-NMR \D20): 8 = 0.75(3H), 1.95(2H), 2.4(2H), 2.85(3H), 3.05(2H), 3.2-3.4(4H), 3.4(3H), 3.5-3.9(9H), 6.95(2H), 7.1-7.2(2H), 7.3-7.4(2H), 7.6(1 H), 7.7-7.8(2H), 7.8(1H) and 8.1(3H) ppm.
Example 119
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-

88
ethoxy-phenyl)-1-(2,4-climethoxy-benzenesulfonyl)-2-oxo-2I3-clihydro-1H-indole-3-yl] amide
1H-NMR (CDCI3): 8 = 1.5-1.9(7H), 2.05(2H), 2.25-2.35(4H), 2.45(4H), 3.0(2H), 3.15-3.3(4H), 3.5(3H), 3.85(3H), 4.15(1 H), 4.25(1 H), 6.4(1 H), 6.55(1 H), 6.7(1 H), 6.85(1 H), 6.9(2H), 7.25(1 H), 7.6(2H) and 8.2(2H) ppm.
Example 120
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-acetylamino-
benzenesulfonyl)-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2I3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.6(2H), 2.0(2H), 2.15-2.25(4H), 2.25-
2.4(5H), 2.5(2H), 2.9-3.1 (4H), 3.5(1 H), 3.6(1 H), 3.8(1 H), 4.0(1 H), 6.8(1 H),
7.0(1 H), 7.25(1 H), 7.3(1 H), 7.6-7.75(4H), 7.8(1 H) and 8.052(3H) ppm.
Example 121
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.35(2H), 1.5-1.9(5H), 2.25-2.35(4H), 2.3(4H), 2.4-
2.8(1 OH), 3.5(3H), 3.75-3.9(5H), 4.1-4.3(2H), 6.4(1 H), 6.55(1 H), 6.7-7.0(3H),
7.05(1 H), 7.25(1 H), 7.9(2H) and 8.1(1 H) ppm.
Example 122
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(2-methoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
'H-NMR (CDCI3): 8 =T.2-1.4(2H), 1.a5(3H), 1.6-1.9(2H), 2.25-2.4(4H), 2.4-
2.8(10H), 3.55(3H), 3.8(2H), 4.1-4.3(2H), 6.8-7.1(8H), 7.25(1H), 7.5(1H),
7.9(1H)and8.15(1H)ppm.
Example 123
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -(4-methoxy-

89
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-fluoro-2-oxo-2I3-dihyclro-1H-inclole-3-yl] amide dihydrochloride
1H-NMR (De-DMSO): 8 = 1.15(3H), 1.5(2H), 2.05(2H), 2.6(2H), 2.8(3H), 3.2-3.8(11H), 3.85(4H), 3.95(1 H), 6.95(2H), 7.1 (2H), 7.15(2H), 7.3(1 H), 7.4(1 H), 7.7(1 H), 7.75(1 H) and 7.95(2H) ppm.
Example 124
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-isopropyl-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.1-1.3(9H), 1.55(2H), 1.7(2H), 1.9(2H), 2.15-2.4(6H),
2.5(2H), 2.8(1 H), 2.9(1 H), 3.1 (1H), 3.6(2H), 3.8(1 H), 4.05(1 H), 6.75(1 H),
6.8(1 H), 6.9(1 H), 6.95-7.05(2H), 7.15(1 H), 7.25(1 H), 7.5(1 H), 7.7(1 H),
7.85(1H)and8.15(1H)ppm.
Example 125
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.25-1.45(21-1), 1.45-1.7(5H), 1.75(2H), 2.25-2.75(12H),
3.55(3H), 3.75(2H), 4.15(1 H), 4.25(1 H), 6.65(1 H), 6.85(1 H), 6.9(1 H),
6.95(1 H), 7.05(1 H), 7.25(1 H), 7.55(1 H), 7.6(2H), 8.1 (1H) and 8.15(1 H) ppm.
Example 126
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-fluoro-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-ylJ amide
1H-NMR (CDCI3): 8 = 1.4-1.6(5H), 1.7(2H), 1.9(2H), 2.2-2.3(4H), 2.45(4H),
3.55(3H), 4.1-4.3(2H), 6.75-7.15(7H), 7.25(1 H), 7.5(1 H), 7.9(1 H) and
8.15(1 H) ppm.
Example 127

90
4-( 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-isopropyl-1-(4-methoxy-benzenesulfonyl)-2-oxo-2)3-clihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.15(6H), 1.2(3H), 1.55(2H), 1.75(2H), 2.0(2H), 2.2-
2.45(6H), 2.45(1 H), 2.55(1 H), 2.75(1 H), 2.95(2H), 3.05(2H), 3.6(2H),
3.75(1 H), 3.85(3H), 4.0(1 H), 6.75(2H), 6.95(2H), 7.0(1 H), 7.15(1 H),
7.25(1 H), 7.7(1 H), 7.8(1 H) and 8.1(2H) ppm;
Example 128
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 8 = 1.2(31-1), 1.35(2H), 1.55(2H), 1.75(2H), 2.2-2.8(12H),
3.5(3H), 3.75(2H), 3.85(3H), 4.15(1 H), 4.2(1 H), 6.4(1 H), 6.55(1 H), 6.7(1 H),
6.85(1 H), 6.9(1 H), 6.95(1 H), 7.25(1 H), 7.6(2H) and 8.1 (2H) ppm.
Example 129
(-)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.55(2H), 1.75(2H), 1.9(2H), 2.2-2.45(6H),
2.55(2H), 2.9(2H), 3.1 (2H), 3.55-3.7(5H), 3.8(1 H), 4.1 (1H), 6.8(1 H),
6.95(1 H), 7.0-7.1 (3H), 7.3(1 H), 7.6(1 H), 7.7(2H) and 8.15(2H) ppm.
Example 130
(+)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1 -(2-methoxy-benzenesUlfonyi)-2-oxo-2,3-uiriydro-1 H-ii idole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(31-1), 1.55(2H), 1.75(2H), 1.9(2H), 2.2-2.45(6H),
2.55(2H), 2.9(2H), 3.1(2H), 3.55-3.7(5H), 3.8(1H), 4.1(1H), 6.8(1H),
6.95(1 H), 7.0-7.1 (3H), 7.3(1 H), 7.6(1 H), 7.7(2H) and 8.15(2H) ppm.

91
Example 131
(-)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.55(2H), 1.75(2H), 1.9(2H), 2.2-2.45(6H),
2.55(2H), 2.95(2H), 3.1 (2H), 3.5-3.7(5H), 3.8(1 H), 3.85(3H), 4.05(1 H),
6.4(1 H), 6.55(1 H), 6.8(1 H), 7.0(1 H), 7.3(2H), 7.65(2H), 8.05(1 H) and 8.1 (1H)
ppm.
Example 132
(+)-4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(31-1), 1.55(2H), 1.75(2H), 1.9(2H), 2.2-2.45(6H), 2.55(2H), 2.95(2H), 3.1 (2H), 3.5-3.7(5H), 3.8(1 H), 3.85(3H), 4.05(1 H), 6.4(1H), 6.55(1H), 6.8(1H), 7.0(1H), 7.3(2H), 7.65(2H), 8.05(1H)and 8.1(1H) ppm.
Example 133
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-5-cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihyclro-1H-indole-3-yl] amide 1H-NMR (CDCI3): 8 = 1.35(2H), 1.5(3H), 1.85(2H), 2.25-2.8(14H), 3.7(2H). 4.1 (1H), 4.2(1 H), 6.5(1 H), 6.9(2H), 7.05(1 H), 7.3(1 H), 7.45-7.7(5H), 8.05(1 H) and 8.15(1 H) ppm.
Example 134
4-^ 1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 -benzenesulfonyl-3-(2-ethoxy-phenyl)-5-isopropyl-2-oxo-2,3-dihydro-1H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.15(6H), 1.2(3H), 1.55(2H), 1.7(2H), 1.95(2H), 2.2-
2.4(5H), 2.45(1 H), 2.55(1 H), 2.75(1 H), 2.9(2H), 3.05(2H)1 3.6(2H), 3.75(1 H), 3.95(1 H), 6.8(2H), 7.0(1 H), 7.2(1 H), 7.3(2H), 7.5(2H), 7.6(1 H), 7.75(1 H), 7.8(1H)and8.15(2H)ppm.

92
Example 135
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[4-chloro-3-(2-
methoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-clihyclro-1H-
indole-3-yl] ester
1H NMR (CDCI3): 6 = 1.43-1.94(7H), 2.24-2.66(7H), 2.86-3.30(3H), 3.60(3H),
3.68(3H), 3.84(1 H), 6.40(1 H), 6.52(1 H), 6.78(1 H), 6.93(1 H), 7.00(1 H), 7.33-
7.20(m), 7.80(1 H), 7.91(1 H), 8.06(1 H).
Example 136
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[4-chloro-3-(2-
methoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H NMR (CDCI3): 8 = 1.43-2.01 (5H), 2.26-2.56(6H), 2.63(1 H), 3.10(2H), 3.25(1 H), 3.50-3.65(4H), 3.73(1 H), 3.84(3H), 6.76(1 H), 6.91-7.07(4H), 7.22-7.37(m),7.81(2H),8.08(2H).
Example 137
4-(1 -Methyl-piperazine-4-yl)-piperidlne-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(2-methoxy-benzenesulfonyl)-2-oxo-2>3-dihydro-1H-
indole-3-yl] amide dihydrochloride
1 H-NMR (De-DMSO): 8 = 1.3(3H), 1.45(2H), 2.05(2H), 2.6(2H), 2.85(3H),
3.2-3.9(15H), 3.9-4.2(4H), 6.8(2H), 7.0(3H), 7.15(1 H), 7.2(1 H), 7.3(1 H),
7.6(1 H), 7.7(2H) and 8.0(1 H) ppm.
Example 138
4-(1-Methyl-piperazine-4-yl)-piperidine-i-carboxylic acid-[3-(2-ethoxy: " phenyl )-5-methoxy-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl] amide dihydrochloride
1H-NMR (De-DMSO): 8 = 1.3(3H), 1.3-1.6(2H), 2.05(2H), 2.65(2H), 2.8(3H), 3.2-3.8(15H), 3.85(3H), 3.9-4.2(4H), 6.7(2H), 6.8(2H), 6.95(1 H), 7.0(2H), 7.3(1 H), 7.6(1 H), 7.7(2H) and 7.9(1 H) ppm.

93
Example 139
4-(1 -Methyl-piperazine-4-yl)-piperidine-1 -carboxylic acid-[3-(2-ethoxy-
phenyl)-5-methoxy-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.2(3H), 1.35-1.6(2H), 1.9-2.1(2H), 2.6(2H),
2.8(3H), 3.2-3.8(12H), 3.8-4.1 (7H), 6.8-6.95(3H), 6.95(1 H), 7.15(2H), 7.2-
7.3(2H), 7.6(1 H), 7.7(1 H) and 7.9(2H) ppm.
Example 140
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[1 -benzenesulfonyl-
3-(2-ethoxy-phenyl)-5-methoxy-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.2(3H), 1.3-1.6(2H), 1.9-2.1 (2H), 2.6(2H), 2.8(3H),
3.2-3.8(14H), 3.85(1 H), 3.95(1 H), 6.8(2H), 6.9(1 H), 6.95(1 H), 7.3(2H), 7.6-
7.8(5H) and 8.0(2H) ppm.
Example 141
4-(1 -Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[6-chloro-3-(2-
methoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
Example 142
4-( 1-Methyl-piperidine-4-yl)-piperazine-1-carboxylic acid-[1-(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-5-isopropyl-2-oxo-2I3-dihydro-1H-
indole-3-yl] ester
'ri-hiviR ^Us-DiviSO): 6 = 0.95(3H), 1.1 (6H), 1.4(2H), 1.65(21!), 2.0(2H),
2.15-2.35(4H), 2.4(2H), 2.55(2H), 2.85(2H), 2.95(1H), 3.15(1H), 3.4(1H),
3.45(3H), 3.65(1 H), 3.7(1 H), 3.85(3H), 3.9(1 H), 6.6(1 H), 6.65(1 H), 6.85(1 H),
6.95(1 H), 7.05(1 H), 7.25(1 H), 7.3(1 H), 7.65(1 H), 7.7(1 H) and 7.85(1 H) ppm.
Example 143

94
4-Piperidine-4-yl-piperazine-1 -carboxylic acid-[5-cyano-1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2)3-dihydro-1H-indole-3-yl]
ester dihydrochloride
1H-NMR (De-DMSO): 8 = 1.0(3H), 1.9(2H), 2.25(2H), 2.8-3.7(15HX 3.75(1 H),
3.85(3H), 3.95(1 H), 4.3(1 H), 6.6-6.7(2H), 7.0(1 H), 7.1 (2H), 7.35(1 H),
7.65(1 H), 7.8(1 H), 7.85(1 H), 7.95(2H), 9.0(NH+) and 11.8(NH+) ppm.
Example 144
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.35(2H), 1.5(3H), 1.55(2H), 1.75(2H), 2.3-2.5(4H),
2.5-2.8(8H), 3.7(2H), 3.85(3H), 4.1 (1H), 4.2(1 H), 6.5(1 H), 6.8-7.0(4H),
7.05(1 H), 7.25(1 H), 7.45(1 H), 7.6(1 H) and 8.0-8.1(3H) ppm.
Example 145
4-(4-Ethyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-
phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 1.1(3H), 1.25(3H), 1.55(2H), 1.55(2H), 1.9(2H), 2.3(1 H), 2.4(4H), 2.55(2H), 2.9-3.2(4H), 3.55(3H), 3.6(2H), 3.8(1 H), 3.85(3H), 4.05(1 H), 6.4(1 H), 6.55(1 H), 6.8(1 H), 7.00(1 H), 7.2-7.4(2H), 7.65(2H), 8.05(1 H) and 8.1(1 H) ppm.
Example 146
4-(4-Propyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-ethoxy-phenyl)-1 -(2I4-dimeth0xy-befizeneSuifonyi;-2-oxo-2,3-uiriydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 5 = 0.9(3H), 1.25(3H), 1.4-1.6(4H), 1.7(2H), 1.9(2H), 2.25(3H), 2.35(2H), 2.55(2H), 2.95
95
Example 147
4-(4-lsopropyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1 H-NMR (CDCI3): 6 = 1.25(3H), 1.45(6H), 1.6(2H), 1.9(2H), 2.3-2.8(8H), 3.1-
3.3(2H), 3.4-3.8(7H), 3.8(1 H), 3.85(3H), 4.05(1 H), 6.4(1 H), 6.55(1 H),
6.8(1 H), 7.0(1 H), 7.2-7.4(2H), 7.6-7.75(2H), 8.05(1 H) and 8.15(1 H) ppm.
Example 148
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[4-methyl-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
Example 149
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-cyano-3-(2-
ethoxy-phenylJ-l-^^-dibromo-benzenesulfonyl^-oxo^.S-dihydro-IH-
indole-3-yl] ester
1 H-NMR (CDCI3): 5 = 1.25(3H), 1.55(2H), 1.75(2H), 1.95(2H), 2.2-2.6(8H), 2.9(2H), 3.0(2H), 3.5(1 H), 3.65(1 H), 3.8(1 H), 4.0(1 H), 6.8(1 H), 7.05(1 H), 7.25(1 H), 7.35(1 H), 7.6-7.8(3H), 7.85(1 H), 8.0(1 H) and 8.3(1 H) ppm.
Example 150
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[4-methoxy-3-(2-
methoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
Example 151
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[4-methoxy-3-(2-methoxy-phenyl)-1 -(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-diriydro-1 H-indole-3-yl] ester

96
Example 152
4-(4-Methyl-piperidine-1 -yl)-piperazine-1 -carboxylic acid-[5-methoxy-3-(2-
ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 5 = 1.25(3H), 1.55(2H), 1.7(2H), 1.9(2H), 2.2-2.3(4H), 2.4(2H), 2.5(2H), 2.9(2H), 3.1 (2H), 3.6(4H), 3.7(3H), 3.75(1 H), 3.8(3H), 4.05(1 H), 6.4(1 H), 6.5-6.6(2H), 6.75(1 H), 6.8(1 H), 6.95(1 H), 7.25(1 H), 7.65(1 H), 7.85(1 H) and 8.05(1 H) ppm.
Example 153
4-Piperazine-1 -yl-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-dimethoxy-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide dihydrochloride
1H-NMR (D6-DMSO): 5 = 1.25(3H), 1.45(2H), 2.0(2H), 2.65(2H), 3.2-
3.8(13H), 3.8-4.1 (6H), 6.6-6.75(2H), 6.9(1 H), 7.0(1 H), 7.25-7.4(2H), 7.7(1 H),
7.8(2H), 7.9(2H), 9.4(NH+), 9.6(NH+) and 11.9(NH+) ppm.
Example 154
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 8 = 1.2-1.4(5H), 1.5(3H), 1.75(2H), 2.4(1 H), 2.5-2.8(12H),
3.5(3H), 3.75(2H), 3.85(3H), 4.15(1 H), 4.2(1 H), 6.4(1 H), 6.55(1 H), 6.7(1 H),
6.85(1 H), 6.9(1 H), 6.95(2H), 7.25(1 H), 7.6(2H) and 8.1 (2H) ppm.
Example 155
4-^4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid^-cyano-l -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (De-DMSO): 8 = 0.9(3H), 1.15(3H), 1.45(2H), 1.7(2H), 2.0(2H),
2.65(2H), 3.05(2H), 3.25-3.8(12H)t 3.8-4.1(7H), 6.7(2H), 6.9CIH), 6.95(1H),
7.3(2H), 7.7(1 H), 7.8(2H) and 7.9(2H) ppm.

97
Example 156
4-(4-Propyl-piperazine-1 -yl-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.35(2H), 1.45-1.55(5H), 1.75(2H), 2.3(3H), 2.4-2.8(10H), 3.7(2H), 4.1(1H), 4.2(1H), 6.45(1H), 6.9(2H), 7.1(1H), 7.3(1H), 7.5(3H), 7.55-7.7(2H), 8.0(1 H) and 8.1 (2H) ppm.
Example 157
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.35(2H), 1.45-1.6(5H), 1.75(2H), 2.25-
2.4(3H), 2.4-2.65(8H), 2.65(2H), 3.5(3H), 3.75(2H), 4.15(1 H), 4.2(1 H),
6.65(1 H), 6.85(1 H), 6.9(1 H), 6.95(1 H), 7.05(1 H), 7.25(1 H), 7.55(1 H),
7.6(2H), 8.1(1 H) and 8.15(1 H) ppm.
Example 158
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide dihydrochloride
1H-NMR (D6-DMSO): 8 = 1.1 (3H), 1.25(6H), 1.45(2H), 2.0(2H), 2.65(2H),
3.3-3.8(13H), 3.8-4.1 (7H), 6.7(2H), 6.95(1 H), 7.0(1 H), 7.3(2H), 7.7(1 H),
7.8(2H) and 7.9(2H) ppm.
Example i by
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.1(1H), 1.25(3H), 1.35(1H), 1.4-1.65(4H),
1.7(1H), 1.85(1H), 2.25-2.75(1 OH), 2.95(1 H), 3.55(1 H), 3.8(1 H), 4.05(1 H),

98
4.2(1 H), 6.8(1 H), 6.9(1 H), 7.0(2H), 7.25(1 H), 7.3(1 H), 7.7(2H) and 8.1-8.25(2H) ppm.
Example 160
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.1-1.35(4H), 1.4-1.75(6H), 1.85(1H), 2.25-
2.75(1 OH), 2.95(1 H), 3.55(1 H), 3.8(1 H), 3.85(3H), 4.0(1 H), 4.2(1 H), 6.8(1 H),
6.95(2H), 7.05(1 H), 7.25(1 H), 7.3(1 H), 7.65(1 H), 7.7(1 H) and 8.05(3H) ppm.
Example 161
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.1(1H), 1.3(3H), 1.35-1.75(4H), 1.75-
1.95(1H), 2.25-2.75(12H), 2.9(1 H), 3.55(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H),
6.8(1 H), 7.0(1 H), 7.15(1 H), 7.2-7.4(3H), 7.6(1 H), 7.7(2H) and 8.15(2H) ppm.
Example 162
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.2(1H), 1.25(3H), 1.35-1.75(6H), 1.85(1H),
2.25-2.75(1 OH), 2.95(1 H), 3.5(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H),
7.0(1 H), 7.25(1 H), 7.3(1 H), 7.5(2H), 7.65(2H), 7.7(1 H) and 8.05-8.2(3H)
ppm.
Example 163
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.35(2H), 1.45-1.6(5H), 1.75(2H), 2.3(2H),

99
2.35(1 H), 2.4-2.8(1 OH), 3.7(2H), 3.85(3H), 4.1 (1H), 4.2(1 H), 6.5(1 H), 6.85-7.0(4H), 7.1(1H), 7.3(1H), 7.5(1H), 7.6(1H), 8.05(1H) and 8.1(2H) ppm.
Example 164
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.25(1H), 1.35(1H), 1.45-1.65(5H), 1.75(2H),
2.2-2.35(3H), 2.35-2.8(1 OH), 3.7(2H), 4.1(1H), 4.2(1H), 6.45(1H), 6.9(2H),
7.1(1H), 7.15(1H), 7.3(2H), 7.5(1H), 7.55-7.65(2H), 8.1(1H) and 8.15(1H)
ppm.
Example 165
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.25(1H), 1.35(1H), 1.45-1.65(5H), 1.75(2H),
2.2-2.35(3H), 2.4-2.8(1 OH), 3.7(2H), 4.1(1 H), 4.2(1 H), 6.4(1 H), 6.8-7.05(4H),
7.15(1 H), 7.3(1 H), 7.5(1 H), 7.6(1 H), 8.1 (1H) and 8.15(1 H) ppm.
Example 166
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.1(1H), 1.25(3H), 1.4-1.95(1 OH), 2.25-
2.75(11H), 2.95(1 H), 3.55(4H), 3.8(1 H), 4.05(1 H), 4.2(1 H), 6.8(1 H),
6.95(lH), 7.05(2H), 7.25(1H), 7.3(1H), 7.55(1H), 7.65(2H) and 3.1(2H) ppr...
Example 167
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2l3-dihydro-1H-indole-3-yl] ester
dihydrochloride

100
1H-NMR (De-DMSO): 8 = 0.95(3H), 1.35(1H), 1.6(1H), 1.95(1H), 2.1 (2H), 2.6(2H), 2.8(3H), 3.0(1 H), 3.2-3.9(12H), 4.25(1 H), 6.95(1 H), 7.1(1 H), 7.4(1 H), 7.6-7.75(3H), 7.8(2H), 7.9(2H), 8.0(1 H) and 8.05(1 H) ppm.
Example 168
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester dihydrochloride
1H-NMR (De-DMSO): 6 = 1.2(3H), 1.35-1.7(2H), 1.85-2.2(2H), 2.6(1 H),
2.8(3H), 3.0(1 H), 3.2-3.8(11H), 3.95(1 H), 4.25(1 H), 7.0(1 H), 7.1(1 H), 7.3-
7.5(2H), 7.5-7.7(2H), 7.8(1 H), 7.95(2H) and 8.1(1 H) ppm.
Example 169
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 1.25(31-0, 1.3-1.9(5H), 2.25-2.7(12H), 2.9(1 H),
3.55(1 H), 3.8(1 H), 4.05(1 H), 4.2(1 H), 6.8(1 H), 7.05(1 H), 7.15(1 H), 7.2-
7.4(3H), 7.6(1 H), 7.7(2H) and 8.15(21-1) ppm.
Example 170
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.15-1.3(4H), 1.4-1.9(4H), 2.3-2.75(12H), 2.95(1 H),
3.55(1 H), 3.8(1 H), 3.85(3H), 3.95(1 H), 4.2(1 H), 6.8(1 H), 6.95(2H), 7.05(1 H),
7.25(1 H), 7.3(1 H), 7.65(1 H), 7.7(1 H) and 8.05(3H) ppm.
Example 171
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester

101
1H-NMR (CDCI3): 5 = 1.1(1H), 1.25(3H), 1.3-1.9(4H), 2.25-3.2(12H), 2.95(1 H), 3.5-3.65(4H), 3.8(1 H), 4.05(1 H), 4.2(1 H), 6.8(1 H), 6.9(1 H), 7.0-7.1 (2H). 7.3(1 H), 7.55(1 H), 7.65(2H) and 8.1 (2H) ppm.
Example 172
4-(4-Methyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester dihydrochloride
1H-NMR (CF3COOD): 5 = 0.5(3H), 1.8(2H), 2.0(2H), 2.5(3H), 2.75(2H), 3.05(3H), 3.1-3.6(16H), 6.0(1H), 6.1(1H), 6.2(1H), 6.45(1H), 6.75(1H), 7.2(1 H), 7.35(1 H), 7.4(1 H) and 7.5(1 H) ppm.
Example 173
4-(4-Propargyl-3-yl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
(4-methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 6 = 1.3-1.5(2H), 1.5(3H), 1.7-1.85(2H), 2.25(1 H), 2.5-
2.8(1 OH), 3.3(2H), 3.5(3H), 3.8(2H), 3.85(3H), 4.1-4.3(2H), 6.4(1 H),
6.55(1 H), 6.7(1 H), 6.85(1 H), 6.9-7.0(2H), 7.3(1 H), 7.6(2H) and 8.1 (2H) ppm.
Example 174
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] ester 1H-NMR (CDCI3): 8 = 1.1 (6H), 1.2(3H), 1.35-1 J5(5H), 1.75-1.95(1 H), 2.25-2.8(9H), 2.95(1 H), 3.5(2H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 7.05(1 H), 7.2(1 H), 7.35(1 H), 7.5(1 H), 7.6-7.7(3H) and 8.05-8.15(3H) ppm.
Example 175
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.1(6H), 1.25(3H), 1.35-1.75(5H). 1.75-1.95(1 H),

102
2.35(1 H), 2.4-2.8(8H), 2.95(1 H), 3.55(1 H), 3.75(1 H), 3.85(3H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 6.95(2H), 7.05(1 H), 7.2(1 H), 7.3(1 H), 7.65(1 H), 7.7(1 H) and 8.05-8.15(3H) ppm.
Example 176
4-(4-Allyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.3-1.5(2H), 1.5-1 J(5H), 1.7-1.85(2H), 2.3-2.8(9H),
3.05(2H), 3.5(3H), 3.75(2H), 3.85(3H), 4.1-4.3(2H), 5.1-5.3(2H), 5.9(1 H),
6.4(1 H), 6.55(1 H), 6.7(1 H), 6.85(1 H), 6.9(1 H), 6.95(1 H), 7.25(1 H), 7.6(2H)
and 8.1 (2H) ppm.
Example 177
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1-(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.1 (6H), 1.25(3H), 1.35-1.95(6H), 2.35(1 H), 2.4-
2.8(9H), 2.95(1 H), 3.55(3H), 3.8(1 H), 4.05(1 H), 4.2(1 H), 6.8(1 H), 6.95(1 H),
7.0-7.1(2H), 7.25(1 H), 7.3(1 H), 7.55(1 H), 7.7(2H) and 8.1(2H) ppm.
Example 178
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
1H-NMR (CDCI3): 8 = 1.1 (3H), 1.35(2H), 1.5(3H), 1.75(2H), 2.25-2.8(13H), 3.8(2H), 4.1(1 M), 4.2^ 1M), 6.45(iH), 6.9(2H), 7.1 (2H), 7.3(1 H), 7.5(3ri), 7.55-7.7(2H), 8.0(1 H) and 8.15(2H) ppm.
Example 179
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-

103
3-yl] amide
1H-NMR (CDCI3): 8 = 1.1(31-1), 1.35(21-1), 1.5(3H), 1.75(2H), 2.25-2.8(13H), 3.55(3H), 3.75(2H), 4.15(1 H), 4.25(1 H), 6.65(1 H), 6.85(1 H), 6.9(2H), 6.95(1H), 7.05(1H), 7.3(1H), 7.55(1H), 7.6(2H), 8.1(1H) and 8.15(1H) ppm.
Example 180
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-fluoro-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
1H-NMR (CDCI3): 5 = 1.1 (3H), 1.25(1H), 1.35(1H), 1.5(3H), 1.55(2H),
1.75(2H), 2.25-2.8(13H), 3.5(3H), 3.7(2H), 4.1(1H), 4.2(1H), 6.45(1H),
6.9(2H), 7.1(1H), 7.15(11-1), 7.3(2H), 7.5(1H), 7.6(2H), 8.1(1H) and 8.15(1H)
ppm.
Example 181
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 6 = 0.9(3H), 1.25-1.4(5H), 1.45-1.65(5H), 1.75(2H), 2.25-
2.8(13H), 3.5(3H), 3.7(2H), 3.9(3H), 4.75(1 H), 6.4(1 H), 6.55(1 H), 6.65(1 H),
6.85(1 H), 6.9(1 H), 7.0(1 H), 7.25(1 H), 7.6(1 H), 7.65(1 H) and 8.1 (2H) ppm.
Example 182
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 6 = 0.9(3H), 1.25-1 4(Sri), 1.45-1.65(on), i./b(2ri), 2.25-
2.8(13H), 3.5(3H), 3.75(2H), 4.75(1 H), 6.65(1 H), 6.85(1 H), 6.9(2H), 7.0(1 H),
7.05(1 H), 7.25(1 H), 7.55(1 H), 7.6(1 H), 7.65(1 H), 8.1 (1H) and 8.1 (1H) ppm.
Example 183
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-

104
methoxy-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl] amide
1H-NMR (CDCb): 5 = 0.9(3H), 1.3(3H), 1.35(2H), 1.45(3H), 1.5(2H), 1.75(2H), 2.25-2.8(13H), 3.7(2H), 3.85(3H), 4.7(1 H), 6.4(1 H), 6.8-7.0(4H), 7.1(1 H), 7.25(1 H), 7.5(1 H), 7.6(1 H) and 8.0-8.1 (3H) ppm.
Example 184
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-isopropoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.25-1.4(5H), 1.4-1.65(5H), 1.75(2H), 2.25-
2.8(13H), 3.7(2H), 4.7(1 H), 6.35(1 H), 6.8(2H), 7.1-7.2(3H), * 7.3(1 H),
7.45(1 H), 7.6(1 H), 8.05(1 H) and 8.1 (2H) ppm.
Example 185
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
dimethoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-
indole-3-yl] ester
1H-NMR (CDCI3): 8 = 1.1(6H), 1.15-1.35(4H), 1.4-1.7(1H), 1.7-1.9(2H),
2.4(1 H), 2.45-2.8(1 OH), 2.95(1 H), 3.5(3H), 3.6(1 H), 3.8(1 H), 3.85(3H),
4.05(1 H), 4.2(1 H), 6.4(1 H), 6.55(1 H), 6.75(1 H), 7.0(1 H), 7.2-7.35(2H), 7.6-
7.7(2H), 8.05(1 H) and 8.1(1 H) ppm.
Example 186
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.1 (6H), 1.25(3H), 1.4-1.95(4H), 2.35(1 H), 2.4-
2.9(1 OH), 2.95(1 H), 3.5(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 6.9(1 H),
7.0(2H), 7.25(1 H), 7.3(1 H), 7.7(2H) and 8.15(2H) ppm.
Example 187

105
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2l3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 1.1(6H), 1.25(3H), 1.35-1.95(6H), 2.35-3.05(1 OH),
3.5(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 7.0(1 H), 7.15(1 H), 7.2-7.4(3H),
7.6(1 H), 7.65(2H)and 8.15(2H) ppm.
Example 188
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 6 = 1.1 (6H), 1.25(3H), 1.35-1.95(4H), 2.35(1 H), 2.4-
2.8(1 OH), 2.95(1 H), 3.5(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 7.05(1 H),
7.15-7.4(4H), 7.6-7.75(2H) and 8.1-8.2(3H) ppm.
Example 189
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2>3-dihydro-1H-indole-3-
yl] ester
1H-NMR (CDCI3): 8 = 0.9(3H), 1.1-1.35(4H), 1.35-1.8(5H), 1.9(1H), 2.2-
2.85(11H), 2.95(1 H), 3.5(1 H), 3.8(1 H), 4.0(1 H), 4.2(1 H), 6.8(1 H), 7.05(1 H),
7.15-7.3(3H), 7.35(1 H), 7.6-7.75(2H) and 8.0-8.15(3H) ppm.
Example 190
3-(2-Ethoxy-phenyl)-1-benzenesulfonyl-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile
1H-NMR (CDCI3): 5 = 0.9(3H), 1.0-1.2(1 H), 1.2-1.35(3H), 1.35(1H), 1.45-1.8(4H), 1.85(1H), 2.2(1 H), 2.25-2.8(1 OH), 2.9(1 H), 3.3(1 H), 3.65(1 H), 3.75-4.1(4H), 6.8(1H), 6.95(1H), 7.25(2H), 7.35(1H), 7.45-7.7(4H), 8.05(1H) and 8.15(2H)ppm.

106
Example 191
3-(2-Ethoxy-phenyl)-1-(2-methoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrite
1H-NMR (CDCI3): 5 = 0.9(3H), 1.2(1H), 1.4(4H), 1.5-1.9(5H), 2.2-2.75(11H),
2.9(1 H), 3.25(1 H), 3.6(3H), 3.75-3.85(2H), 3.9-4.05(2H), 4.15(1 H), 6.75-
6.95(3H), 7.05(1 H), 7.15-7.3(3H), 7.5-7.65(2H), 8.1(1 H) and 8.15(1 H) ppm.
Example 192
3-(2-Ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile
a) 4-(4-Propyl-piperazine-1-yl)-piperidine-1-carboxylic acid-tert-
butylester
42 g (0.50 mol) sodium acetate were added in portions to 73 g (0.25 mol) N-propylpiperazine dihydrobromide in 1 I methanol at 40° C. Subsequently, this was cooled to 0° C and 50 g (0.25 mol) Boc-4-piperidon and 16 g (0.25 mol) sodium cyanoborohydride, in portions, were added, one after the other. Everything was then stirred at room temperature for 16 h. The reaction mixture was concentrated in a vacuum and then distributed between ethyl acetate and 1M NaOH. The organic phase was separated, washed with 1M NaOH, H2O and cone. NaCI solution, dried and concentrated in a vacuum. The residue was chromatographically purified over silica gel (mobile phase: MeOH/CH2CI2 = 1/15). 43.6 g of the product were obtained.
b) i-ripeii«jiric-4-yl-4-propyl-piperazinG trihydrochloride -
43.5g (0.14 mol) of the intermediate product 192a were dissolved in 500 ml methanol and then 100 ml 5-6 M isopropanolic HCI were slowly added at 40° C, wherein intermittently a powerful gas development began and the product partially crystallised. The gas development had ended after 30 minutes. After this, another 50 ml 5-6 M isopropanolic HCI were added, and everything was

107
stirred for 1 h at 40° C. It was allowed to cool, and the precipitated product was isolated. 34 g of the product were obtained.
c) 3-(2-Ethoxy-phenyl)-3-hydroxy-5-iodo-1,3-dihydro-indole-2-one
8.0 g (1.65 mol) magnesium shavings were overlaid with 40 ml ether, and after the addition of a small quantity iodine, were carefully heated until the reaction kicked off. 66.3 g (0.33 mol) 2-bromo-1-ethoxybenzene dissolved in 200 ml ether was dropped in to the boiling solution so slowly that the reaction continually proceeded at a low boil. Subsequently, with slight cooling to 20° C, 30 g (0.11 mol) 5-iodine-isatin in 800 ml water-free tetrahydrofurane was added in by drops. After this, everything was stirred for 30 minutes more at room temperature. The reaction solution was poured into an aqueous NH4CI solution while being stirred. This aqueous phase was extracted a number of times with ethyl acetate and the combined aqueous phases were washed with water four times, dried and concentrated in a vacuum, after which a solid precipitated slowly, which was isolated and dried. 33.6 g of the intermediate product were obtained.
d) 3-(2-Ethoxy-phenyl)-3-hydroxy-2-oxo-2)3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
37 g (94 mmol) of the intermediate product 192c and 11 g (94 mmol) zinc cyanide were placed in 300 ml DMF and all were rapidly heated to 90-95° C. After this, 1.6 g (1.4 mmol) Pd[Ph3P]4 were added in two portions within 20 minutes. After an additional 30 minutes, the reaction mixture was poured on to icy water and extracted with ethyl acetate. The organic phase was washed with water and saturated NaCI in isolation, dried and concentrated in a vacuum. The residue obtained was crystallised from c little ethyl acetate and the crystals were isolated. 24 g of the product were obtained.
e) 3-Chloro-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
10 g (34 mmol) of the intermediate product 192d and 5.6 ml (68 mmol) pyridine were dissolved in 120 ml CH2CI2. After this, everything was cooled

108
to 0° C and 3.7 ml (51 mmol) SOCI2 were added by drops. The reaction mixture was stirred for 1 h more. Then everything was carefully placed in icy water, the organic phase was separated, washed a number of times with H20, dried and concentrated in a vacuum. The residue obtained was treated with n-pentane and the resulting solid was isolated, after which 9.9 g of the product were obtained.
f) 2-[5-Cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indole-3-yl]-
malonic acid dimethylester
3.8 g (96 mmol) NaH (60%) were carefully added to 200 ml water-free DMF. Then 12 ml (105 mmol) malonic acid dimethylester were added slowly by drops at 10° C. Everything was stirred for 30 minutes more at room temperature. Subsequently, 10 g (32 mmol) of the intermediate product 192e was added in portions and the reaction mixture was stirred for 15 minutes more. This mixture was carefully mixed in by stirring to 1 M HCI and then everything was cooled, wherein a precipitate resulted, which was isolated and recrystallised from CH2CI2/pentane. 10.7 g of the product were obtained.
g) [5-Cyano-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]-
methyl acetate
10.7 g (26 mmol) of the intermediate product 192f were dissolved in 10 ml ethanol. 100 ml 2 M caustic soda solution was added, and the mixture was stirred at room temperature for 1 h. The reaction batch was mixed in by stirring to 1 M HCI, wherein a precipitate formed that was isolated and dried. This solid was transferred to a 1-1 container and heated to 150° C, wherein this foamed as a result of a gas development. It was allowed to cool after the reaction had completed. The residue was treated with methanol and ths precipitate obtained was isolated. 6.4 g of the product were obtained.
h) [5-Cyano-3-(2-ethoxy-phenyl)-2-oxo-2)3-dihydro-1 H-indole-3-yl]-ethanoic acid
36 ml 2 M NaOH were added to 5.9 g (16.8 mmol) of the intermediate product 192g in 25 ml ethanol, and everything was stirred at room

109
temperature for 3 h. Then the reaction mixture was acidified with 6 ml ethanoic acid and diluted with water. A solid precipitated overnight, which was isolated and dried. 5.2 g of the product were obtained.
i) 3-(2-Ethoxy-phenyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1-yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile 1.8 g (16.3 mmol) t-BuOK were carefully added to 1.9 g (5.4 mmol) of the intermediate product 192b in 25 ml water-free DMF at 0°C. Then 2 g (5.4 mmol) of the intermediate product 192h, 0.8 g (5.4 mmol) HOBT, 2.9 ml (20.9 mmol) Et3N and finally, in portions, 1.1 g (5.4 mmol) EDAC were added, one after the other. The reaction mixture was then stirred at room temperature for 16 h. This mixture was then mixed by stirring into a 5% K2C03 solution, wherein a precipitate formed that was isolated and dried. 2.6 g of the product were obtained.
j) 3-(2-Ethoxy-phenyl)-1-(4-methoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile
47 mg (0.42 mmol) t-BuOK were added to 0.2 g (0.38 mmol) of the intermediate product 192i in 4 ml DMF at 0°C. Everything was stirred for 1 h at 0° C. Subsequently, 86 mg (0.42 mmol) 4-methoxybenzenesulfonylchloride were added in portions at 0° C and everything was stirred for 16 h. The reaction batch was mixed in by stirring to 1 M NaOH and the resulting precipitate was isolated. This was then recrystallised from methanol, wherein 0.15 g of the product resulted.
1i!-NMR (CDGI3): 5 = C.9(3H), 1.G-1.2(1H), 1.2-1.3(3H),- 1.35(1 H), 1.45-1.75(4H), 1.85(1H), 2.25(1 H), 2.3-2.8(1 OH), 2.9(1 H), 3.3(1 H), 3.65(1 H), 3.75-3.95(5H), 4.0(1 H), 6.8(1 H), 6.9-7.0(3H), 7.25(2H), 7.35(1 H), 7.55(1 H)
and 8.0-8.15(3H)ppm.

110
Example 193
3-(2-Ethoxy-phenyl)-1-(2-fluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile
1H-NMR (CDCI3): 8 = 0.9(3H), 1.15(1H), 1.25-1.4(4H), 1.4-1 J5(4H), 1.8(1H), 2.1-2.8(11H), 2.9(1 H), 3.3(1 H), 3.65(1 H), 3.8(1 H), 3.85(1 H), 3.95(1 H), 4.0-4.15(2H), 6.8(1H), 6.95(1H), 7.15(1H), 7.2-7.4(3H), 7.6(2H), 8.15(1H) and 8.2(1 H)ppm.
Example 194
3-(2-Ethoxy-phenyl)-1-(2,4-dimethoxy-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-carboxylic-acid nitrile
1H-NMR (CDCI3): 5 = 0.9(3H), 1.2(1H), 1.3-1.45(4H), 1.45-1.9(5H), 2.2-2.8(11H), 2.9(1 H), 3.25(1 H), 3.55(1 H), 3.75-3.9(5H), 3.95(1 H), 4.05(1 H), 4.15(1 H), 6.4(1 H), 6.55(1 H), 6.85(1 H), 6.9(1 H), 7.2(1 H), 7.25(1 H), 7.55(2H) and8.1(2H)ppm.
Example 195
3-(2-Ethoxy-phenyl)-1-(2,4-difluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
1H-NMR (CDCI3): 8 = 0.9(3H), 1.15(1H), 1.2-1.4(4H), 1.4-1 J5(3H), 1.85(1H),
2.15-2.7(11H), 2.9(1 H), 3.3(1 H), 3.65(1 H), 3.75-4.0(2H), 4.1(1 H), 6.8(1 H),
6.85(1H), 6.9-7.0(2H), 7.3(3H), 7.6(1H), 8.1(1H) and 8.2(1H) ppm.
Example 196
3-(2-Ethoxy-phenyl)-1-(4-chloro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-propyl-piperazine-1 -yl)-piperidine-1 -yl]-ethyl}-2f3-clihydro-1 H-indole-5-
carboxylic-acid nitrile
1H-NMR (CDCI3): 8 = 0.9(3H), 1.0(1H), 1.15(1H), 1.25-1.8(4H), 1.85(1H),

111
2.15-2.8(11H), 2.95(1 H), 3.3(1 H), 3.6(1 H), 3.7-3.95(3H), 4.0-4.15(1 H), 6.8(1 H), 6.95(1 H), 7.3(3H), 7.45(2H), 7.55(1 H) and 8.0-8.1 (3H) ppm.
Example 197
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -
benzenesulfonyl-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
1H-NMR (CDCI3): 8 = 1.05(6H), 1.3(2H), 1.5(3H), 1.75(2H), 2.3(1 H), 2.5-
2.8(11H), 3.7(2H), 4.1 (1H), 4.2(1 H), 6.45(1 H), 6.9(2H), 7.05(1 H), 7.3(1 H),
7.5(3H), 7.55-7.65(2H), 8.05(1 H) and 8.15(1 H) ppm.
Example 198
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 5 = 1.05(6H), 1.35(3H), 1.55(31-1), 1.75(2H), 2.3(1 H), 2.45-
2.8(11H), 3.5(3H), 3.75(2H), 4.15(1 H), 4.25(1 H), 6.7(1 H), 6.85(1 H), 6.9(2H),
6.95(1 H), 7.05(1 H), 7.25(1 H), 7.55(1 H), 7.6(2H), 8.1 (1H) and 8.15(1 H) ppm.
Example 199
4-(4-isopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 8 = 1.05(6H), 1.35(3H), 1.5(3H), 1.75(2H), 2.3(1 H), 2.5-
2.8(11H), 3.7(2H), 3.85(3H), 4.0(1 H), 4.2(1 H), 6.5(1 H), 6.85-7.0(4H),
7.05(1 H), 7.3(1 H), 7.5(1 H), 7.55(1 H) and 7.95-8.1(3H) ppm.
Example 200
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihyclro-1H-indole-3-
yl] amide
1H-NMR (CDCI3): 8 = 1.05(6H), 1.25(1 H), 1.35(1 H), 1.5(3H), 1.75(2H),

112
2.3(1 H), 2.45-2.8(11H), 3.7(2H), 4.1 (1H), 4.2(1 H), 6.45(1 H), 6.9(2H), 7.1(1H), 7.15(1H), 7.3(2H), 7.5(1H), 7.6(2H), 8.1(1H) and 8.15(1H) ppm.
Example 201
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (De-DMSO): 8 = 1.05(6H), 1.25(1H), 1.35(1H), 1.45(3H), 1.75(2H),
2.3(1 H), 2.5-2.8(11H), 3.7(2H), 4.1(1 H), 4.2(1 H), 6.4(1 H), 6.8-7.05(4H),
7.15(1 H), 7.3(1 H), 7.5(1 H), 7.6(1 H), 8.1 (1H) and 8.2(1 H) ppm.
Example 202
4-(4-ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
methoxy-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (D6-DMSO): 8 = 0.95(3H), 1.1 (3H), 1.15(2H), 1.6(2H), 2.2-2.7(12H),
3.75(2H), 3.85(3H), 3.9(2H), 6.9-7.0(2H), 7.1(2H), 7.3(1H), 7.5(1H),
7.55(1 H), 7.6(1 H), 7.8(1 H), 7.85(1 H) and 7.95(2H) ppm.
Example 203
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(2,4-
difluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-
3-yl] amide
1H-NMR (CDCI3): 6 = 1.1 (3H), 1.25(1H), 1.35(1H), 1.45(3H), 1.75(2H), 2.25-
2.8(12H), 3.7(2H), 4.1 (1H), 4.2(1 H), 6.4(1 H), 6.8-7.05(4H), 7.15(1 H),
7.35(1 H), 7.5(1 H), 7.6(1 H), 8.1(1 H) and 8.2(1 H) ppm.
Example 204
4-(4-Ethyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-fluoro-
benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-yl]
amide
1H-NMR (CDCI3): 8 = 1.1(3H), 1.3(2H), 1.5(3H), 1.8(2H), 2.2-2.8(13H),

113
3.7(2H), 4.1 (1H), 4.2(1 H), 6.4(1 H), 6.9(2H), 7.05-7.25(3H), 7.3(1 H), 7.45(1 H), 7.6(1 H), 8.05(1 H) and 8.15(2H) ppm.
Example 205
4-(4-Propyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
1H-NMR (CDCI3): 8 = 0.9(3H), 1.3(2H), 1.4-1.6(5H), 1.75(2H), 2.2-2.8(13H),
3.7(2H), 4.1(1 H), 4.2(1 H), 6.4(1 H), 6.9(2H), 7.05-7.2(3H), 7.3(1 H), 7.45(1 H),
7.6(1 H), 8.0(1 H) and 8.15(2H) ppm.
Example 206
4-(1-Methyl-piperidine-4-yl)-piperazine-1 -carboxylic acid-[1 (4-methoxy-1 -
benzenesulfonyl)-5-cyano-2-oxo-3-(2-ethoxyphenyl)-2,3-dihydro-1H-indole-
3-yl] ester
1H-NMR (CDCI3): 8 = 1.25(3H), 1.6-1.9(4H), 2.1 (2H), 2.25-2.45(4H), 2.5(1 H),
2.6(1 H), 2.9-3.2(4H), 3.6(2H), 3.8(1 H), 3.85(3H), 4.0(1 H), 6.8(1 H), 6.95(2H),
7.05(1 H), 7.25(1 H), 7.35(1 H), 7.65(1 H), 7.7(1 H) and 8.05(2H) ppm.
Example 207
4-(4-lsopropyl-piperazine-1 -yl)-piperidine-1 -carboxylic acid-[5-cyano-1 -(4-
fluoro-benzenesulfonyl)-3-(2-ethoxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-3-
yl] amide
1H-NMR (D6-DMSO): 8 = 1.05(6H), 1.35(2H), 1.5(3H), 1.75(2H), 2.3(1 H),
2.5-2.8(11H), 3.7(2H), 4.1(1 H), 4.2(1 H), 6.45(1 H), 6.9(2H), 7.1-7.25(3H),
7.3(1 H), 7.45(1 H), 7.6(1 H), 8.05(1 H) and 8.15(2H) ppm.
Example 208 3-(2-Ethoxy-phenyl)-1-(4-fluoro-benzenesulfonyl)-2-oxo-3-{2-oxo-2-[4-(4-
propyl-piperazine-1 -y1)-piperidine-1 -yi]-ethyl}-2,3-dihydro-1 H-indole-5-
carboxylic-acid nitrile
1H-NMR(CDCI3): 8 = 0.9(3H), 1.1(1H), 1.15CIH), 1.25-1.4(4H), 1.45-1.6(2H),

114
1.7(1H), 1.85(1H), 2.15-2.7(12H), 2.95(1 H), 3.3(1 H), 3.65(1 H), 3.75-3.95(3H), 4.05(1 H), 6.8(1 H), 6.95(1 H), 7.15(2H), 7.25-7.4(3H), 7.55(1 H), 8.05(1 H) and 8.15(2H) ppm.

115
udE Claim
1. Compound or compounds of the general formula (I),

wherein
A is C6-io-aryl, which can be substituted with a maximum of four residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)0-2-CN, CF3, OCF3, CONH2, CONH(CrC4 alkyl), CON(CrC4 alkyl)(CrC4 alkyl), NHCHO, NHCONH2, N(C0-C4 alkylene)CONH2, N(C0-C4 alkylene)CONH(CrC4 alkyl), NHCOCH3, N02, (CH2)o-2-OH, 0-CrC6 alkyl, (CH2)o-2-0-CrC4 alkyl, O-C0-C4 alkylene-phenyl, phenyl, CrC6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,
B is an aromatic or partially aromatic monocyclic or bicyclic Ce-io that can be substituted with the residues R6, R7, R8 and / or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)0-2-CN, CF3, OCF3, CONH2, CONH(CrC4 alkyl), CON{C,-C, a!ky!){C;-C4 alky!), NHCHO, N(C0-4 ?lkylen*)C0NH(Ci-C4 alkyl), NHCOCH3, N02, OH, 0-CrC4 alkyl, (CH2)o-2-0-(CH2)o-3-CH3, 0-Co-C4 alkylene-phenyl, phenyl, CrC6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,
R1 is hydrogen, CrC6 alkyl, OH, 0-(Ci-C4 alkyl), N(Ci-C4 alkyl)(CrC4 alkyl), CN, CONH2. OCF3, CF3, Br, F, CI, J, N02.

116
NHCHO, NHCO(Ci-C4 alkyl) or NHCONH2l
R2 is hydrogen, C1-C4 alkyl, 0-(Ci-C4 alkyl), CI or F,
R3 is a residue {\N)-(X)-(Y)-Z, wherein
W is C1-C4 alkylene, (C0-C4 alkylene)-O-(C0-C4 alkylene) or
(C0-C4 alkylene)-NR15-(Co-C4 alkylene), wherein R15 is
hydrogen or Ci-C4 alkyl,
X is CO, S02, (C=NH) or (C=N-CN) and
Y is a residue selected from the group consisting of

wherein Y can additionally be substituted with R10 and / or R11, wherein
R10 is hydrogen, Ci-C6 alkyl, C2-C6 alkenyi, C2- R11 is hydrogen, CrC6 alkyl, C2-C6 alkenyi, C2-C6 alkynyl, OH, 0-CrC4 alkyl, O-C0-C4 alkylene-phenyl, NH2, NH(CrC4

117
alkyl) or N(CrC4 alkyl)(CrC4 alkyl), and
Z is a residue selected from the group consisting of

wherein Z can additionally be substituted with R12 and / or R13, wherein
R12 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, O-C^ alkyl, O-C0-C4 alkylene-phenyl, NH2, NH(d-C4 alkyl) or N(CrC4 alkyl)(CrC4 alkyl),
R13 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, 0(d-C4 alkyl), O-C0-C4 alkylene-phenyl, NH2, NH(d-C4 alkyl) or N(CrC4 alkyl)(CrC4 alkyl),
R14 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or Co-C4 alkylene-phenyl, and
their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

118
Compound or compounds according to Claim 1, wherein A is a phenyl ring that can be substituted with a maximum of four residues R4 and B is a phenyl ring that can be substituted with the residues R6, R7, R8 and / or R9, wherein the residues R4, R6, R7, R8 and R9 shall have the meanings cited in Claim 1,
and their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.
Compound or compounds according to Claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl, (CH2)0-2-O-(CH2)o-2-CH3 ad CrC6 alkyl,
B is a phenyl ring that can be substituted with the residues R6, R7, R8 and / or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and CrC6 alkyl,
R1 is hydrogen. CN. F. CI, d^, alkyl, OH or 0-(Ci-4 alkyl),
R2 is hydrogen,
R3 is a residue (W)-(X)-(Y)-Z, wherein
W is 0, CH2NH, NHCH2, OCH2, CH20 or NH,
X is CO,
Y is a residue selected from the group consisting of

119
Z is a residue selected from the group consisting of


wherein Z can additionally be substituted with R12 and / or R13, wherein
R12 is hydrogen or C1-C4 alkyl,
R13 is hydrogen or C1-C4 alkyl and wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl,
ana their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.
4. Compound or compounds according to Claim 1, wherein

120
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, 0-CrC4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3 and CrC6 alkyl,
B is a phenyl ring that can be substituted with the residues R6 and / or R7 wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-d-C4 alkyl and CrC6 alkyl,
R1 is hydrogen, F, CI, CH3, CN, CH2CH3, OCH3 or OCH2CH3,
R2 is hydrogen,
R3 is a residue (W)-(X)-(Y)-Z, wherein W is O, CH2 or NH, X is CO, Y is a residue selected from the group

wherein Z can be substituted with R12 and / or R13, wherein R12 is hydrogen or C1-C4 alkyl,

121
R13 is hydrogen or C1-C4 alkyl and
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl,
and their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.
5. Compound or compounds according to Claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl, (CH2)o-2-0-(CH2)o-2-CH3, and d-C6 alkyl,
B is a phenyl ring that can be substituted with the residues R6 and / or R7, wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl, and Ci-C6 alkyl,
R1 is CI, CH3, CN, CH2CH3 or OCH3,
R2 is hydrogen,
R3 is a residue (W)-(X)-(Y)-Z, wherein
W is CH2, O or NH,
X is CO,
Z is a residue

Y is a residue


122
wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl,
and their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.
6. Compound or compounds according to Claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O-C1-C4 alkyl and C1-C4 alkyl,
B is a phenyl ring that is substituted with the residues R6 and / or R7, wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O-C1-C4 alkyl, and CrC6 alkyl,
R1 is hydrogen, CI, CH3, CN, CH2CH3, OCH3 or OCH2CH3,
R2 is hydrogen,
R3 is a residue (WHXHY)-Z, wherein
W is CH2, O or NH,
X is CO,

and Z is a residue
Y is a residue

123

wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkynyl,
and their tautomeric, enantiomeric and / or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.
7. Medicaments containing at least one compound according to any of the Claims 1 to 6 as well as, where applicable, customary pharmaceutical auxiliary agents.
8. Use of at least one compound according to any of the Claims 1 to 6 for the treatment and / or prophylaxis of vasopressin-dependent or oxytocin-dependent diseases.
9. Use of at least one compound according to any of the Claims 1 to 6 for the treatment and / or prophylaxis of at least one disease, selected from the group consisting of diabetes insipidus, nocturnal enuresis, incontinence and diseases in which coagulation disorders occur and / or for the delay of micturition.
10. Use of at least one compound according to any of the Claims 1 to 6 for the treatment and / or prophylaxis of at least one disease selected from the group consisting of hypertension, pulmonary hypertension,

124
cardiac insufficiency, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, oedemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and peptic ulcer, emesis, recurrent emesis during chemotherapy and / or travel sickness.
11. Method for the therapeutic and / or prophylactic treatment of a
mammal that requires treatment, by administration of at least one
compound according to any of the Claims 1 to 6 for the treatment of
diseases.
12. Use of at least one compound according to any of the Claims 1 to 6 for the treatment of affective disorders.
13. Use of at least one compound according to any of the Claims 1 to 6 for the treatment of anxiety disorders and / or stress-dependent anxiety disorders.
14. Use of at least one compound according to any of the Claims 1 to 6 for the treatment of memory disturbances and / or Alzheimer disease.
15. Use of at least one compound according to any of the Claims 1 to 6 for the treatment of psychoses and / or psychotic disorders.
16. Use of at least one compound according to any of the Claims 1 to 6

125 for the treatment of Cushing Syndrome.
17. Use of at least one compound according to any of the Claims 1 to 6 for the treatment of sleep disorders.
18. Compound or compounds according to any of the Claims 1 to 6 for use as a medicament.
19. Method for the production of a compound according to the general formula (I)

wherein the residues R1, R2, R3, A and B have the meaning mentioned in one of the Claims 1 to 6, characterised in that, according to the method variant (A), isatin or isatin derivative, known per se, which is substituted with the residues R1 and R2, is reacted by the introduction of the residue A into the 3-position while maintaining the corresponding 3-hydroxy-oxindole-derivativesr followed by the introduction of the B-SO2 residue at the ring nitrogen and exchange of the residue R3 with the 3-hydroxy group or another suitable nucleofuge according to procedures known per se
or, according to method variant (B), the isatin or isatin derivative, known per se, which is substituted with the residues R1 and R2, is

126
reacted first by the introduction of the residue B-SO2 at the ring nitrogen and then by introduction of the residue A into the 3-position while maintaining the corresponding 3-hydroxy-oxindole derivatives, followed by the exchange of the residue R3 with the 3-hydroxy group or another suitable nucleofuge according to procedures known per se.




127 Abstract
The present invention relates to novel oxindole derivatives of the general
formula (I),

wherein the substitutes A, B, R1, R2 and R3 are as defined in Claim 1, and medicaments containing the same for the prophylaxis and / or treatment of vasopressin-dependent or oxytocin-dependent diseases.

Documents:

199-MUMMP-2007-CLAIMS(AMENDED)-(8-1-2010).pdf

199-MUMMP-2007-REPLY TO EXAMINATION REPORT(8-1-2010).pdf

199-MUMNP-2007-ABSTRACT(13-5-2009).pdf

199-mumnp-2007-abstract(complete)-(8-1-2007).pdf

199-mumnp-2007-abstract(granted)-(21-6-2010).pdf

199-mumnp-2007-abstract.doc

199-mumnp-2007-abstract.pdf

199-MUMNP-2007-ASSIGNMENT(15-4-2010).pdf

199-mumnp-2007-cancelled pages(8-10-2010).pdf

199-MUMNP-2007-CLAIMS(13-5-2009).pdf

199-mumnp-2007-claims(complete)-(8-1-2007).pdf

199-mumnp-2007-claims(granted)-(21-6-2010).pdf

199-mumnp-2007-claims.doc

199-mumnp-2007-claims.pdf

199-MUMNP-2007-CORRESPONDENCE(13-5-2009).pdf

199-MUMNP-2007-CORRESPONDENCE(15-4-2010).pdf

199-MUMNP-2007-CORRESPONDENCE(16-4-2010).pdf

199-mumnp-2007-correspondence(ipo)-(22-6-2010).pdf

199-mumnp-2007-correspondence-others.pdf

199-mumnp-2007-correspondence-received.pdf

199-mumnp-2007-description (complete).pdf

199-MUMNP-2007-DESCRIPTION(COMPLETE)-(13-5-2009).pdf

199-mumnp-2007-description(complete)-(8-1-2007).pdf

199-mumnp-2007-description(granted)-(21-6-2010).pdf

199-MUMNP-2007-FORM 1(8-2-2007).pdf

199-mumnp-2007-form 18(8-2-2007).pdf

199-mumnp-2007-form 2(13-5-2009).pdf

199-mumnp-2007-form 2(complete)-(8-1-2007).pdf

199-mumnp-2007-form 2(granted)-(21-6-2010).pdf

199-MUMNP-2007-FORM 2(TITLE PAGE)-(13-5-2009).pdf

199-mumnp-2007-form 2(title page)-(complete)-(8-1-2007).pdf

199-mumnp-2007-form 2(title page)-(granted)-(21-6-2010).pdf

199-MUMNP-2007-FORM 26(13-5-2009).pdf

199-MUMNP-2007-FORM 3(13-5-2009).pdf

199-mumnp-2007-form-1.pdf

199-mumnp-2007-form-2.doc

199-mumnp-2007-form-2.pdf

199-mumnp-2007-form-5.pdf

199-mumnp-2007-form-pct-ib-304.pdf

199-MUMNP-2007-OTHER DOCUMENT(15-4-2010).pdf

199-mumnp-2007-pct-search report.pdf

199-MUMNP-2007-PETITION UNDER RULE 137(13-5-2009).pdf

199-MUMNP-2007-PETITION UNDER RULE 137(16-4-2010).pdf

abstract1.jpg


Patent Number 241149
Indian Patent Application Number 199/MUMNP/2007
PG Journal Number 26/2010
Publication Date 25-Jun-2010
Grant Date 21-Jun-2010
Date of Filing 08-Feb-2007
Name of Patentee ABBOTT GMBH & CO., KG
Applicant Address MAX-PLANCK-RING 2, 65205 WIESBADEN
Inventors:
# Inventor's Name Inventor's Address
1 LUBISCH WILFRIED DREIKREUZWEG 58, 69151 NECKARGEMUND
2 OOST,Thorsten Gaisbergstr. 21, 69115 Heidelberg
3 WERNET, Wolfgang Freiheistrasse 73, 67434 Neustadt
4 UNGER, Liliane Wollstr.129, 67065 Ludwigshafen
5 HORNBERGER, Wilfried Goldener Winkel 14, 67434 Neustadt
6 GENESTE, Herve Rehbachstr.42, 67141 Neuhofen
PCT International Classification Number C07D209/00
PCT International Application Number PCT/EP2005/007631
PCT International Filing date 2005-07-13
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 102004033834.5 2004-07-13 Germany
2 60/587,407 2005-07-13 Germany